The QualityStocks Daily Thursday, August 4th, 2022

Today's Top 3 Investment Newsletters

MarketBeat(CCXI) $50.4300 +109.17%

QualityStocks(OG) $0.7624 +90.60%

Early Bird(YELL) $6.7000 +42.25%

The QualityStocks Daily Stock List

NanoViricides (NNVC), Wall Street Resources, QualityStocks, StockMarketWatch, Stock Preacher, PennyStocks24, Beacon Equity Research, InvestorSoup, MarketClub Analysis, BUYINS.NET, TradersPro, Jason Bond, SuperStockTips, StockProfessors, Penny Stocks Finder, StockHideout, Penny Stock Craze, MissionIR, SmarTrend Newsletters, MarketBeat, Stock Roach, LightningStockPicks, PennyStockShark, Stock Analyzer, FeedBlitz, CoolPennyStocks, USA Market News, Standout Stocks, HotOTC, Tiny Gems, TopStockAnalysts, Market Wrap Daily, Broad Street, PennyOmega, OTCPicks, Penny Stock Finder, StreetAuthority Daily, InvestorPlace, HotStockChat, Stock Beast, Greenbackers, Stock Market Watch, DrStockPick, CRWEWallStreet, OTCReporter, CRWEFinance, The Street, Stockwire, Stock Rich, BullRally, Stock Source, BestOtc, StockEgg, AllPennyStocks, All about trends, CRWEPicks, MicrocapVoice, Zacks, StreetInsider, Agora Financial, PennyTrader Publisher, ProfitableTrading, Penny Pick Finders, Penny Invest, SmallCapVoice, ProTrader, InvestorsUnderground, MicroCapDaily, MegaPennyStocks, The Online Investor, MarketClub, Real Pennies, RedChip, Round Up the Bulls, PennyToBuck and StockHotTips reported earlier on NanoViricides (NNVC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

NanoViricides Inc. (NYSE American: NNVC) (FRA: NV3P) is a nano-biopharmaceutical firm that is engaged in the discovery, development and commercialization of therapies for treating viral infections and helping advance the care of patients with these life-threatening ailments.

The firm has its headquarters in Shelton, Connecticut and was incorporated in 2005, on April 1st by Anil R. Diwan. It operates in the health care sector, under the biotech and pharma sub-industry.

The company centers its clinical programs and research on certain anti-viral therapies and is working on adding to them its current portfolio of products via an in-licensing strategy and its clinical development and internal discovery programs. It is currently engaged in the application of Nano medicine technologies to the intricate issues of viral illnesses.

The enterprise’s product pipeline is made up of an anti-HIV nanoviricide dubbed HIVCide; DengueCide developed for treating all Dengue viruses; Nanoviricide eye drops for viral ailments that affect the external eye; and an injectable and an anti-influenza oral broad-spectrum nanoviricide known as FluCide, developed for both outpatients and hospitalized patients. The enterprise also develops a treatment for viral acute necrosis dubbed HerpeCide IntraOcular Injection and a formulation indicated for the treatment of ocular herpes keratitis, genital herpes, recurrent herpes labialis, herpes, chickenpox, PHN and shingles, dubbed HerpeCide Dermal Topical and Eye Drops. In addition to this, it is also engaged in HerpeCide program expansion drug projects for various herpes viruses; and researching and developing other nanoviricides for treating different indications and viruses.

The firm recently entered into an agreement with TheraCour Pharma Inc. to target encephalitis, conjunctivitis, dengue and Ebola. The development of cures for these ailments, which presently have no cures, will not only significantly boost the growth of both companies but also improve share prices and encourage more investments into the companies.

NanoViricides (NNVC), closed Thursday's trading session at $3.65, up 48.374%, on 27,360,248 volume. The average volume for the last 3 months is 27.019M and the stock's 52-week low/high is $1.04/$7.86.

InVivo Therapeutics (NVIV)

QualityStocks, OurHotStockPicks, Xtremepicks, Real Pennies, TraderPower, TheStockAdvisor, StockMarketWatch, BullRally, BUYINS.NET, CoolPennyStocks, HotOTC, MadPennyStocks, PennyInvest, PennyStockVille, SmallCapVoice, StockEgg, StockRich, OTC Stock Review, SmallCap Fortunes, TheMicrocapNews, MarketBeat,, Weekly Wizards, TopPennyStockMovers, Buzz Stocks, Top Pros' Top Picks, TheStockAdvisors, InvestmentHouse, InvestorPlace, M2 Communications, PennyTrader Publisher, NYC Marketing Inc, Stock Market Watch, OTCtipReporter, The Street, Streetwise Reports, PennyStockScholar, Barchart, StockOodles, Schaeffer's, News and MarketClub Analysis reported earlier on InVivo Therapeutics (NVIV), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) (FRA: 04IC) is a clinical-stage research and biotechnology firm that is focused on the development and commercialization of biopolymer scaffolding devices which are used to treat spinal cord injuries.

The firm is based in Cambridge, Massachusetts and was incorporated in January 2005 by Robert Langer, Frank M. Reynolds and Joseph P. Vacanti. It operates in the healthcare sector, under the medical equipment and devices sub-industry.

The company’s objective is to change the treatment of spinal cord injuries by modulating the healing environment to facilitate cell growth and survival. Currently, it is focused on using polymers as a platform technology to develop therapies that will enhance function in patients who experienced traumatic spinal cord injuries and got paralyzed as a result.

The enterprise’s pipeline comprises of an investigational bio-resorbable polymer scaffold developed for implantation at the injured site in a spinal cord, known as a Neuro-Spinal Scaffold implant. The scaffold has been designed to encourage functional cells to fill in the cavity that develops at the injury site in a spinal cord. Its success has the potential to improve motor and sensory function, leading to a better quality of life for patients.

The U.S. FDA recently announced its acceptance of the firm’s preclinical module, which brings them one step closer to complete HDE submission. The firm is now enrolling acute spinal cord injury patients into its INSPIRE 2 study which has been designed to expand upon clinical evidence of its spinal scaffold implant from its INSPIRE 1 study. Final approval from the FDA for its neuro-spinal scaffold implant will not only allow the company to help patients with spinal cord injuries but also bring in more investments into the firm, which will boost the company’s growth.

InVivo Therapeutics (NVIV), closed Thursday's trading session at $8, up 80.9955%, on 38,340,441 volume. The average volume for the last 3 months is 38.34M and the stock's 52-week low/high is $3.50/$20.225.

Minerva Neurosciences (NERV)

StockMarketWatch, MarketBeat, MarketClub Analysis, TraderPower, StreetInsider, Schaeffer's, BUYINS.NET, Barchart, Greenbackers, Investors Alley,, QualityStocks, Zacks, TradersPro Morning, WealthMakers and One Hot Stock reported earlier on Minerva Neurosciences (NERV), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Minerva Neurosciences Inc. (NASDAQ: NERV) (FRA: 4MN) is a clinical stage biopharmaceutical firm that is engaged in developing and commercializing therapies for treating central nervous system disorders.

The firm has its headquarters in Waltham, Massachusetts and was incorporated in 2007, on April 23rd by Rogerio Vivaldi Coelho. Prior to its name change in 2013, the firm was known as Cyrenaic Pharmaceuticals Inc. It operates as part of the pharmaceutical and medicine manufacturing industry, under the health care sector, in the biotech and pharma sub-industry, and serves consumers in the U.S.

The company is party to a license agreement with Mitsubishi Tanabe Pharma Corp, which involves the development, sale and importation of roluperidone internationally, excluding the Asia Pacific region.

The enterprise’s product pipeline comprises of a soluble recombinant neuregulin-1b1-protein form dubbed MIN-301, which is indicated for the treatment of Parkinson’s disease as well as other neurodegenerative disorders; and a compound dubbed roluperidone (MIN-101), which is undergoing a phase 3 clinical trial evaluating its effectiveness in treating schizophrenia. It also develops MIN-202, which is indicated for the treatment of major depressive disorder and insomnia; and MIN-117, which has also been developed to treat major depressive disorder. MIN-202 is a selective orexin 2 receptor antagonist while MIN-117 has been designed to block 5-HT1A; which is a subtype of the serotonin receptor.

The firm is focused on advancing its roluperidone formulation, which it believes will play a significant role in the treatment of schizophrenia. The treatment’s success will not only fulfill a highly unmet need among patients with the ailment but also boost investments into the firm, which will have a positive effect on the company’s growth.

Minerva Neurosciences (NERV), closed Thursday's trading session at $4.7, up 75.3731%, on 37,673,210 volume. The average volume for the last 3 months is 37.632M and the stock's 52-week low/high is $2.51/$17.04.

Onion Global Ltd (OG)

QualityStocks and MarketClub Analysis reported earlier on Onion Global Ltd (OG), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Onion Global Ltd (NYSE: OG) is a lifestyle brand platform that is focused on the incubation, marketing and distribution of future, fashionable and fresh brand products in Asia.

The firm has its headquarters in Guangzhou, the People’s Republic of China and was incorporated in 2009. It serves consumers in China as well as internationally.

The company has over 4,000 brands on its platform, which includes about 85 brand partners that directly work with the company. These brand partners offer more than 20 categories of lifestyle products that include wellness products, fast fashion, food and beverage products, baby and maternal products and beauty products. The company’s platform offers users an enjoyable online shopping experience and a wide product selection, which disrupts the traditional lifestyle retail landscape in China. This helps reshape the consumer culture and lifestyle shopping in the country.

The enterprise’s products include products of its own private labels, as well as products sourced from 3rd party product suppliers that include both authorized distributors and resellers of 3rd party brands and 3rd party brand partners. It sells its product offerings through CosyFans and O’Mall, which are both self-operated social e-commerce platforms. O’Mall can be accessed by consumers through WeChat/Weixin mini programs. The enterprise is also engaged in the provision of marketplace services and subscription services.

The firm recently launched its first new retail showroom, dubbed Ziplab, in Guangzhou. Ziplab is a multi-super brand store that offers different fashion categories. This move aids in the firm’s expansion of its existing sales channels from online to offline and is bound to have a positive effect on the firm’s sales as well as its growth.

Onion Global Ltd (OG), closed Thursday's trading session at $0.7624, up 90.6%, on 5,941,200 volume. The average volume for the last 3 months is 5.858M and the stock's 52-week low/high is $0.3201/$10.89.

Nutex Health (NUTX)

We reported earlier on Nutex Health (NUTX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Nutex Health Inc. (NASDAQ: NUTX) is a technology-enabled healthcare services firm that is engaged in the provision of healthcare services.

The firm has its headquarters in Houston, Texas and was incorporated in 2011. It operates as part of the health information services industry, under the healthcare sector. The firm serves consumers around the globe, with a primary focus on those in the United States.

The enterprise operates through the Population health management division and the Hospital division. The Hospital division is involved in operating and owning about 21 facilities which are located in 8 different states. This division is also involved in the operation and implementation of various health care models, including specialty hospitals, micro-hospitals and hospital outpatient departments. On the other hand, the Population health management segment is involved in the operation and owning of provider networks like IPAs (Independent Physician Associations). This division’s cloud-based proprietary technology platform also aggregates data across a range of information systems, sources and settings to create a holistic view of each provider and patients, while also facilitating care delivery. The enterprise’s Management Services Organizations offer administrative, management, and other support services to its affiliated physician groups and hospitals.

The company recently provided an update on its growth strategy, which showed that it had already launched two new micro-hospitals and was planning to increase the number of its facilities to 12. Its CEO noted that with their competitive advantages in the marketplace, the company was well positioned for strong growth and creating value for its shareholders.

Nutex Health (NUTX), closed Thursday's trading session at $3.53, up 3.5191%, on 834,925 volume. The average volume for the last 3 months is 831,030 and the stock's 52-week low/high is $2.45/$52.80.

Kopin Corporation (KOPN)

TradersPro, Wall Street Resources, MarketClub Analysis, MarketBeat, Greenbackers,, QualityStocks, Zacks, SmarTrend Newsletters, Cabot Wealth, StockMarketWatch, TraderPower, InvestorPlace, SmallCapVoice, SmallCapInvestorDaily, Wall Street Daily, Early Bird, Daily Trade Alert, Daily Market Beat and Schaeffer's reported earlier on Kopin Corporation (KOPN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Kopin Corporation (NASDAQ: KOPN) (LON: 0JRR) (FRA: KOC) is a company focused on inventing, developing, manufacturing and selling sub-assemblies, micro-displays and hand-held systems and associated components for various products.

The firm has its headquarters in Westborough, Massachusetts and was incorporated in 1984, on April 23rd by John C.C. Fan. It operates as part of the electronic components industry, under the technology sector. The firm serves consumers internationally, with a focus on Europe, the Asia-Pacific and the United States.

The company operates through its wholly owned subsidiaries: NVIS Inc. and Forth Dimension Displays Ltd, which are located in Virginia and Scotland respectively. Its NVIS subsidiary provides high-resolution, near-eye display systems designed for high-fidelity immersive simulation and immersive training while the Forth Dimension subsidiary provides ferroelectric LCOS devices for high-resolution imagers and spatial light modulators. The company generates most of its revenues from the Americas.

The enterprise provides organic light emitting diode displays, liquid crystal on silicon displays/spatial light modulators, miniature active-matrix liquid crystal displays, optical lenses, backlights, application specific integrated circuits and headset systems. Its products are used in consumer virtual reality and augmented reality wearable headsets systems, 3D optical inspection systems, medical, public safety and industrial headsets, avionic, soldier, simulation defense, armored vehicle and training applications.

The firm recently entered into a supply contract with a new Korean 3D AOI client. This will allow the firm to supply its high performance, high speed spatial light modulators to leading manufacturers in Korea as well as other key manufacturers in Germany, Japan and China. This will in turn bring in additional revenues and help create value for the firm’s shareholders.

Kopin Corporation (KOPN), closed Thursday's trading session at $1.44, off by 3.3557%, on 1,251,114 volume. The average volume for the last 3 months is 1.251M and the stock's 52-week low/high is $1.0201/$7.02.

DecisionPoint Systems (DPSI)

Wall Street Resources, TaglichBrothers, QualityStocks, Penny Dreamers, StockGuru, Pumps and Dumps, Investor News Source, MarketBeat, OTCJournal, Penny Stocks VIP, FeedBlitz, SmallCapVoice, Zacks, The Green Baron, TheMicrocapNews, TopPennyStockMovers, TradeThesePicks and RedChip reported earlier on DecisionPoint Systems (DPSI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

DecisionPoint Systems Inc. (NYSE American: DPSI) (FRA: RS7) is an enterprise mobility systems integrator that is engaged in the integration and provision of enterprise mobility and wireless applications solutions which deliver improved operational and productivity advantages to its customers by enabling them to move business decision points closer to their consumers.

The firm has its headquarters in Laguna Hills, California and was incorporated in 1985, on July 5th. It operates as part of the software-application industry, under the technology sector. The firm serves consumers in the United States.

The enterprise is focused on making enterprise software applications accessible anywhere, anytime. It uses mobility, wireless and RFID technologies. The enterprise installs, repairs and deploys mobile computing and wireless systems like mobile computers and application software and related data capture equipment, which includes radio frequency identification readers and bar code scanners for the retail, healthcare, wholesale distribution, warehousing and distribution and field sales and service industries. It also provides project management and deployment, and lifecycle management services, as well as managed services like project management, technology acquisition, consulting, software integration and development, repair services, deployment, service desk, end of life disposal and reverse logistics services. This is in addition to providing a software platform dubbed Mobile Conductor which offers complete in-vehicle solutions, and a software platform that has been designed to manage RFID installations, known as VizeTrace.

The company recently acquired two companies; Boston Technologies and Advanced Mobile Group. This move strengthens the company’s position in the direct store delivery and transportation verticals and may open it up to new opportunities. This will, in turn, positively influence its revenues and growth.

DecisionPoint Systems (DPSI), closed Thursday's trading session at $5.99, up 3.8128%, on 10,456 volume. The average volume for the last 3 months is 10,456 and the stock's 52-week low/high is $3.10/$14.22.

Centogene NV (CNTG)

MarketClub Analysis, StocksEarning, MarketBeat, StockMarketWatch, BUYINS.NET, StreetInsider, Schaeffer's and FreeRealTime reported earlier on Centogene NV (CNTG), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Centogene NV (NASDAQ: CNTG) (ETR: 39K) (FRA: 39K) is a biotechnology firm that is focused on rare illnesses. It transforms real-world genetic and clinical data, as well as other data into actionable information for pharmaceutical firms, physicians and patients.

The firm has its headquarters in Rostock, Germany and was incorporated in 2006 by Christoph Ehlers and Arndt Rolf. It operates as part of the diagnostics and research industry, under the healthcare sector. The firm serves consumers around the globe.

The company is party to collaboration and license agreements with Twist Bioscience Corp, Takeda Pharmaceutical Company Ltd, Fraport AG, Bauer Laboratoriums GmbH, Pfizer Inc. and Shire International GmbH. It operates through the Covid-19 testing, Diagnostics and Pharmaceutical segments.

The enterprise is involved in the development of a data and biological repository, which include heterogenetic, phenotypic and epidemiologic data that improves methods for detecting and monitoring rare hereditary illnesses. The repository also offers solutions that accelerate the development of orphan medications. The enterprise also offers a range of services, which include biomarker discovery, epidemiological insights, early patient identification and recruitment, target discovery and patient monitoring; and genetic sequencing and diagnostics services to labs, physicians or hospitals, through distributors as well as directly. This is in addition to providing coronavirus testing solutions, which include antigen and PCR testing services.

The firm has expanded its mitapivat partnership with Agios Pharmaceuticals Inc., which will allow it to offer lab support to Agio’s trials on the effectiveness and safety of Mitapivat in treating PK deficiency in children. The success and approval of this formulation will not only benefit patients with this indication but also bring in additional revenues and investments into both firms.

Centogene NV (CNTG), closed Thursday's trading session at $1.61, up 3.871%, on 14,551 volume. The average volume for the last 3 months is 14,551 and the stock's 52-week low/high is $1.34/$11.61.

UpHealth Inc. (UPH)

MarketBeat reported earlier on UpHealth Inc. (UPH), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

UpHealth Inc. (NYSE: UPH) (FRA: 5XVO) is a digital health services firm that is engaged in the provision of healthcare services.

The firm has its headquarters in Delray Beach, Florida and was incorporated by Mariya Pylypiv and Chirinjeev Kathuria. It operates as part of the health information services industry, under the healthcare sector. The firm serves consumers around the globe.

The company’s mission is to use technology to connect people directly with licensed pharmacists and physicians while providing health products which support healthier communities and individuals. It operates through the Virtual care infrastructure segment, Integrated care management segment and Services segment.

The enterprise offers patient-centric digital health technologies and technology-enabled services to integrate care and manage health in the areas of virtual care infrastructure, integrated care management and services. Its solutions include a full-service retail and compounding licensed pharmacy dubbed MedQuest Pharmacy, which dispenses prescribed drugs shipped to patients directly; and a platform known as HelloLyf from Glocal, which delivers specialty consultations and primary care. The enterprise also provides an integrated care management platform known as the Syntranet Core Platform; and a provider of unified digital health tools and telemedicine solutions known as Cloudbreak.

The company recently entered into a partnership with Parsley Health, which will involve providing remote language interpretation services to the latter company’s patients. The languages to be interpreted include Korean, French, Spanish and American sign language. This move will open up the company to new growth opportunities while extending its global reach.

UpHealth Inc. (UPH), closed Thursday's trading session at $0.6526, up 1.5878%, on 303,212 volume. The average volume for the last 3 months is 301,650 and the stock's 52-week low/high is $0.45/$6.39.

Hecla Mining Company (HL)

MarketClub Analysis, SmarTrend Newsletters, InvestorPlace, Schaeffer's, Wyatt Investment Research,, StocksEarning, MarketBeat, Top Pros' Top Picks, TopStockAnalysts, StreetAuthority Daily, Market Report, The Street, Money Morning, Zacks,, Jason Bond, Kiplinger Today, Daily Trade Alert, Today's Financial News, StreetInsider, QualityStocks, Wall Street Grand, Trades Of The Day, TheStockAdvisors, Streetwise Reports, StockOodles, Gryphon Digest, TradersPro, The Wealth Report, Penny Detectives, National Inflation Association, SureMoney, TradingAuthority Daily, Stockhouse, Darwin Investing Network, ChartAdvisor, Options Elite, PennyStockLive, INO Market Report, Wall Street Daily, Penny Sleuth, Profit Confidential, ProfitableTrading, TraderPower, The Growth Stock Wire, Daily Markets, Greenbackers, Forbes, DrStockPick, Wealth Insider Alert, TradingMarkets, WealthMakers, Investopedia, CustomerService, CRWEWallStreet, CRWEPicks, CRWEFinance, Weiss Research, BestOtc, Barchart, Daily Wealth,, AllPennyStocks, PennyToBuck, MonsterStocksPicks, Residual Income Report, Money and Markets, Rockwell Trading, Investing Futures, Stock Stars, Traders For Cash Flow, StockHotTips, Trade of the Week, InvestorGuide, Investor Update, Investor Guide, Investing Lab, PennyOmega and SmallCapVoice reported earlier on Hecla Mining Company (HL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Last week, the Prime Minister of India, Narendra Modi, launched the country’s first global bullion exchange in an effort to facilitate transparency within the precious metals market. This will make it easier for small jewelers and bullion dealers to trade in the market and lead to uniform pricing for gold in the country.

In a statement at the inauguration, Modi said that India was laying strong claim in the global financial services sector through this exchange launch. While the National Commodity and Derivatives Exchange and the Multi Commodity Exchange provide gold futures contracts in India, there wasn’t any physical exchange to purchase gold — until now.

India is currently the second-largest consumer of gold globally. Its bullion exchange, dubbed the India International Bullion Exchange, will sell physical gold and silver. It will be based in GIFT City in the western region of Gujarat State.

Nirmala Sitharaman, the country’s minister of finance, stated that the launch of the bullion exchange was a major step and would afford India better strength for price negotiation globally. Currently, gold is strictly regulated in the country, with only nominated agencies and banks that are approved by its Central Bank being allowed to import gold into the country and sell it to jewelers and dealers.

In a statement, the exchange stated that with its technology-based solutions, the India International Bullion Exchange would facilitate the shift of the country’s precious metals market toward a structure that was more organized by giving qualified jewelers unfettered access to gold imports through the mechanism created by the exchange. Jewelers with a net worth of Rs 25 crore ($3.17 million) and more will be allowed to participate in the exchange. Institutes and NRIs will also be allowed to participate in the exchange after they register with the International Financial Services Centre Association.

The biggest consumer of gold currently, China operates a market where all imported and domestically produced gold can be sold and bought.

Last year, India imported roughly 1,070 tons of gold, which is an increase from its 2020 figure of 651 tons. Somasundaram PR, the regional chief executive officer of the World Gold Council in India, stated that the country’s moves aimed at monetizing gold would also gain support from the transparent trading system of bullion in Gujarat International Finance Tec-City.

Households in India own approximately 25,000 tons of gold collectively, which is passed from generation to generation. For a while now, India has been working toward monetizing these holdings in a bid to decrease imports.

This bullion exchange is likely to give entities such as Hecla Mining Company (NYSE: HL) an additional platform where they can sell their gold in this major market in India.

Hecla Mining Company (HL), closed Thursday's trading session at $4.74, up 7.483%, on 6,743,810 volume. The average volume for the last 3 months is 6.713M and the stock's 52-week low/high is $3.44/$7.66.

Fiverr International Ltd. (FVRR)

InvestorPlace, MarketBeat, Schaeffer's, Trades Of The Day, TradersPro, Zacks, Daily Trade Alert, The Street, MarketClub Analysis, StreetInsider, Top Pros' Top Picks, BUYINS.NET, The Online Investor, Kiplinger Today, InvestorsUnderground, The Stock Dork and StockMarketWatch reported earlier on Fiverr International Ltd. (FVRR), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Fiverr (NYSE: FVRR), a company with a mission to revolutionize how the world works together, was featured in a recent analysis report that discussed Fiverr’s performance as remote work has become increasingly common. The report, written by LikeFolio Founder Andy Swan, reads...

To read the full report and view the infographic, please visit

About Fiverr International Ltd.

Fiverr’s mission is to revolutionize how the world works together. The company exists to democratize access to talent and to provide talent with access to opportunities so anyone can grow their business, brand or dreams. From small businesses to Fortune 500, over 4 million customers worldwide worked with freelance talent on Fiverr in the past year, ensuring their workforces remain flexible, adaptive and agile. With Fiverr’s Talent Cloud, companies can easily scale their teams from a talent pool of skilled professionals from over 160 countries across more than 550 categories, ranging from programming to 3D design, digital marketing to content creation, from video animation to architecture. For more information, visit

Fiverr International Ltd. (FVRR), closed Thursday's trading session at $40.24, up 8.5514%, on 3,540,461 volume. The average volume for the last 3 months is 3.511M and the stock's 52-week low/high is $29.0403/$238.88.

Pinterest Inc. (PINS)

InvestorPlace, Kiplinger Today, Schaeffer's, The Street, MarketClub Analysis, MarketBeat, Trades Of The Day, Daily Trade Alert, StocksEarning, Zacks, The Online Investor, Top Pros' Top Picks, StreetInsider, Wealth Insider Alert, Investopedia, INO Market Report, StreetAuthority Daily, StockMarketWatch, BUYINS.NET, Early Bird, InvestmentHouse, CNBC Breaking News, InvestorsUnderground, TradersPro, Market Intelligence Center Alert, Investment House, Investing Daily, FreeRealTime, AllPennyStocks, QualityStocks, StockEarnings and Trading Tips reported earlier on Pinterest Inc. (PINS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Pinterest (NYSE: PINS), the operator of a popular social networking site for sharing photos, ideas, recipes and more, was featured in a recent analysis report. The piece discusses Pinterest’s unique positioning as compared to others in the...

To read the full report and view the infographic, please visit

About Pinterest Inc.

Pinterest operates and maintains a social networking site. The company serves customers worldwide, providing an online venue for personal photos, ideas, oddities, decorations, places to visit, recipes, and other items. For more information about the company, visit

Pinterest Inc. (PINS), closed Thursday's trading session at $22.53, up 0.40107%, on 11,690,665 volume. The average volume for the last 3 months is 11.328M and the stock's 52-week low/high is $16.14/$66.00.

The QualityStocks Company Corner

Golden Matrix Group Inc. (NASDAQ: GMGI)

The QualityStocks Daily Newsletter would like to spotlight Golden Matrix Group Inc. (NASDAQ: GMGI).

  • Esports industry maturing, attracting growing audience via star-studded tournaments, ticket sales, merchandise, live social media events
  • Industry expected to reach $12.5 billion at a CAGR of 21.9% by 2030
  • GMGI recently featured on Benzinga’s Esports Listmakers Series, CEO reveals upcoming launch of Esports platform
  • GMGI delivers easily customizable, configurable, modular solutions for B2B operators, recently achieved 15 consecutive profitable quarters

The global Esports market is maturing into a multi-faceted entertainment enterprise, complete with tournaments, celebrities, and social media influencers. Golden Matrix Group (NASDAQ: GMGI), a developer and licensor of online gaming platforms, systems, and gaming content, aims to leverage this trend by adding an Esports platform to its growing portfolio of B2B iGaming and Esports solutions.

Golden Matrix Group Inc. (NASDAQ: GMGI), based in Las Vegas, Nevada, is an established gaming technology company that develops and owns online gaming IP and builds turnkey online casino solutions for gaming operators as well as configurable and scalable white-label gaming platforms for international customers, located primarily in the Asia-Pacific region. GMGI’s gaming IP includes tools for marketing, acquisition, retention and monetization of users. The company’s platform can be accessed through both desktop and mobile applications.

GMGI’s sophisticated software automatically declines any gaming or redemption requests from within the United States, in strict compliance with U.S. law.

Golden Matrix, through a subsidiary, also runs a pay-to-enter prize competition in the United Kingdom and Ireland.

The company’s shares began trading on the Nasdaq under the symbol ‘GMGI’ on March 17, 2022. Golden Matrix shares were previously traded on the OTCQX Best Market.

For the quarter ended January 31, 2022, the company reported revenue of $8.88 million, an increase of 355% over the same quarter one year earlier. Net income for the three-month period was $349,379, up from $52,158 a year earlier. It was the company’s 14th consecutive profitable quarter.

In December 2021, Golden Matrix announced it had entered into a purchase agreement to acquire a controlling ownership interest in UK-based RKingsCompetitions Ltd., one of Ireland’s and the United Kingdom’s leading independent online competition companies. RKings presents customers with paid and free entry routes to competitions that offer a range of prizes, including residential properties, luxury and exotic motor vehicles, holiday packages, technology packages and cash. The competitions are currently open only to residents of Ireland and the United Kingdom. Golden Matrix acquired an 80% ownership interest in RKings for cash and stock. The company also secured an option to purchase the remaining 20 percent interest of RKings, subject to certain requirements.

In March 2022, Golden Matrix announced it had applied for a Mexican gaming permit and, once approved, expects to offer online gaming in Mexico as well as roll out the RKings tournament business globally.


Golden Matrix Group develops fully operational online casino turnkey solutions as well as highly modular, configurable and scalable gaming platforms for its international customers in an effort to promote user acquisition, engagement, retention and monetization. The provided white label gaming platform is unparalleled in both mobile and desktop website deployment, proving compatible throughout all major operating systems and web browsers. In addition, the platform enhances the client’s ability to cater to various gaming scenarios including but not limited to transaction management and a range of loyalty and reward programs. Moreover, user engagement is optimized through the ability to accommodate both free and paid games.

The company’s GM-X System (and recently its next generation GM-Ag System) is considered the industry standard, granting access to over 10,000 games from more than 25 game providers. Through the GM-X System, Golden Matrix offers the industry’s most extensive game portfolio. The company’s gaming partners dominate the global online gaming market to deliver innovative games and premium brand titles. The GM-X System offers payment gateways that integrate with third party platforms or digital wallets. It supports all major currencies and offers multiple language options. The system’s data analytics provide the operator with a 360-degree view of the gaming platform’s performance.

GMGI currently supports over 500 unique casino brands and over 6 million players.

Market Outlook

Online gaming and sports betting sites and apps are increasingly taking market share from traditional location-based casinos. Widespread internet service availability and increasing use of mobile phones for playing online games from homes and public places is driving the market, according to a report from Grand View Research. In addition, factors such as easy access to online gambling, legalization and cultural approval, corporate sponsorships, and celebrity endorsements are also contributing to market growth. The growing availability of cost-effective mobile applications across the globe is further expected to fuel market growth.

This trend is only expected to accelerate as millennials reach their peak earning years and Gen Z youth begin to complete their education and move into careers. These generations are completely comfortable with online recreation, and with using technology like digital wallets and digital gameplay that underpins online gaming.

The global online gambling market was valued at $53.7 billion in 2019 and is expected to grow at a CAGR of 11.5% from 2020 to 2027 to reach a value of $127.3 billion, according to Grand View Research, with much of the growth expected from the U.S. and Asia. Even Europe, the most mature gaming market, is expected to grow at a rate of 20-25% year-over-year.

Management Team

Brian Goodman is CEO of Golden Matrix Group. He has more than 20 years of diverse senior management experience and business development roles within the technology and internet gaming industries. He has a tertiary science qualification as well as a marketing and sales background. His previous roles have been entrepreneurial and include CEO and senior management positions in smaller organizations, which he founded or in which he held equity, as well as multinational organizations.

Cathy Feng is COO at Golden Matrix. She is a co-founder of GMGI and holds a Master of Commerce degree. She has 10 years of experience as a financial officer in the technology and internet gaming industries. In past management positions, she interpreted, analyzed and presented financial and operation information to facilitate business decisions, grow companies and resolve complex problems. In addition, she has skills in marketing, business development, leadership and strategic planning.

Omar Jimenez is CFO and Chief Compliance Officer at GMGI. Prior to joining the company, he was CFO and COO of Alfadan Inc., a supplier of marine outboard engines. He has held senior financial management and operational positions at public and private companies including NextPlay Technologies, American Leisure Holdings, US Installation Group and Onyx Group. He holds various accounting professional certifications, including CPA and CPCU, and degrees in finance, accounting and business.

Henry Zhang is Chief Technology Officer at Golden Matrix. He oversees all aspects of development, integration and deployment of GMGI’s technology systems. He plays a key role in evolving GMGI’s technology business to lead and shape the industry. He is responsible for developing and scaling new businesses, including online gaming, eSport and P2P Systems. He was instrumental in launching the GM-X system and has been with the company for more than six years.

Golden Matrix Group Inc. (NASDAQ: GMGI), closed Thursday's trading session at $4.18, up 0.722892%, on 7,047 volume. The average volume for the last 3 months is 6,972 and the stock's 52-week low/high is $3.29/$10.72.

Recent News

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

  • CNS Pharmaceuticals is a U.S.-based drug innovator developing novel chemotherapy agents capable of taking the fight against cancerous tumors across the blood-brain barrier to directly attack cancerous growths of the central nervous system
  • The company’s lead candidate is an anthracycline named Berubicin, which has previously shown promise among glioblastoma (“GBM”) patients in a safety study — particularly for one who remains cancer-free more than 15 years later
  • CNS is enrolling patients in the United States, Italy, France, Spain, and Switzerland, for the global Phase 2 clinical trial to measure Berubicin’s potential to match or exceed the effectiveness of Lomustine, a standard-of-care chemotherapy agent used to treat GBM
  • Berubicin has achieved fast track and orphan drug status from the FDA, opening priority regulatory pathways for the drug if it continues to demonstrate successes through the trial process

Glioblastoma (“GBM”) is a brain cancer that has no cure at the present time and few treatment options for patients. It is the most aggressive primary brain tumor, affecting approximately 13,000 newly diagnosed patients each year in the United States with an average survival time of less than a year after diagnosis. New research has found that a ketogenic diet is feasible and safe for individuals with astrocytomas. A ketogenic diet is low in carbohydrates and high in fat. Astrocytomas are brain tumors that usually begin in cells known as astrocytes, which support nerve cells and occur in the brain or spinal cord. For their study, the researchers recruited 25 patients with astrocytomas who were each required to follow the Atkins diet and fast intermittently during an eight-week period. The modified ketogenic diet includes foods such as fish, butter, heavy cream, eggs, leafy green vegetables and bacon. The participants visited a dietician prior to the study then every two weeks after. For five days a week, each of them was required to follow the diet, which combined high amounts of fat and carbohydrate restriction. For the remaining two days, they were required to fast, consuming no more than 20% of their recommended daily calorie amount. It should be noted that the study, whose findings were reported in the online issue of “Neurology,” wasn’t designed to determine if a modified ketogenic diet could improve survival rates or slow down the growth of tumors. Patients therefore need to stick to the treatment regimen ordered by their oncologist, the current shortcomings of those treatments not withstanding, as entities such as CNS Pharmaceuticals Inc. (NASDAQ: CNSP) seek for better treatments for central nervous system and brain cancers.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Thursday's trading session at $0.23, up 4.7359%, on 172,605 volume. The average volume for the last 3 months is 170,369 and the stock's 52-week low/high is $0.20/$1.73.

Recent News

Odyssey Group International Inc. (OTC: ODYY)

The QualityStocks Daily Newsletter would like to spotlight Odyssey Group International Inc. (OTC: ODYY).

  • The medical care needs of military personnel are once again in the spotlight following a political dust-up over service members’ exposure to environmental hazards at burn pits
  • Another long-standing concern among service personnel is the treatment of concussive brain injuries
  • Although no FDA-approved prescription drug currently exists for treating concussions, medical product developer Odyssey Health Inc. is testing a device-drug combination designed to stop concussion injury in its tracks to avoid long-term harm
  • Odyssey Health’s product would use an inhaler-like device to deliver the special medication into the nasal cavity for better uptake into the central nervous system, keying on its demonstrated ability to cross the blood-brain barrier

U.S. military service members’ healthcare concerns landed a new place in the spotlight during the past month when outraged veterans and veteran-friendly politicians called attention to a sudden reversal of fortune for a Congressional bill that promised expanded benefits to service members exposed to environmentally hazardous burn pits used in Iraq, Afghanistan, and elsewhere in the years after Sept. 11, 2001. Odyssey Health (OTC: ODYY), a company focused on developing unique, life-saving medical products, today announced the launch of its new corporate website. Consistent with the company’s recent name change, the new website was designed to better reflect Odyssey Health’s mission and focus while also improving communication strategies with current and potential shareholders, institutions, and various scientific and financial publications. “The launch of our new website is an important next step in the ongoing evolution of Odyssey and will enable us to provide more transparent communications with our shareholders and other stakeholders,” said Odyssey Health CEO Michael Redmond. “We are excited to offer our website visitors an optimal user experience that facilitates seamless access to the information they need through a well-designed interface while elevating the Odyssey brand. We remain committed to providing timely and easily accessible updates not only through our website but across all of our corporate social media platforms, as we continually work on our research, as well as spread the important message about the need to treat concussions around the world.” To view the full press release, visit

Odyssey Group International Inc. (OTC: ODYY) is a medical technology company focused on developing lifesaving medical products that offer technological and clinical advantages over current standards of care.

The company’s portfolio of product technologies is diverse, featuring four unique medical products in development. Odyssey’s goal is to deliver superior products with enhanced clinical utility and market potential, thereby yielding a high rate of return for its shareholders and partners. It is guided by a senior management team with significant experience relating to refining technologies, building commercial systems and forging strategic partnerships.

Product Portfolio


Odyssey has two pharmaceutical products in development:

  • PRV-002 is a novel compound for the treatment of concussion, which currently has no FDA-approved drug. In pre-clinical studies, PRV-002 has been shown to significantly improve both neuroscore and memory score following injury in rats subjected to concussion models. Importantly, the first-in-class novel neurosteroid demonstrated no drug-related toxicity in these trials.
    • PRV-002 is currently being evaluated in a phase I clinical trial for the treatment of concussion, with phase II trials planned for launch in Fall 2022. Odyssey has also highlighted the potential of PRV-002 for additional indications such as Alzheimer’s disease, Parkinson’s disease, ALS and chromic traumatic encephalopathy (CTE).
  • PRV-001 is a novel compound intended to treat Niemann-Pick disease, a rare neurodegenerative-lysosomal storage disorder that affects an estimated 1 in 150,000 individuals in the U.S., demonstrating a 5x higher incidence in Middle Eastern populations.
    • Odyssey expects to receive Orphan Drug designation from the FDA for PRV-001, which would accelerate its pathway to FDA approval and provide seven years of market exclusivity.

Medical Devices

Odyssey is also developing two medical device candidates:

  • CardioMap® is intended to provide early, non-invasive testing for heart disease. The system offers a number of potential advantages over traditional EKGs, including requiring less training to operate, offering heightened sensitivity and coming in a small and portable form factor. CardioMap is being developed for a 510(k) regulatory pathway, which requires a study to demonstrate equivalence to legacy EKG offerings.
    • When approved, CardioMap is expected to be the only device in its class that has a predictive value, illustrating ‘grey’ areas where deterioration has begun but not yet led to pathology. Odyssey expects this feature to provide a powerful incentive for doctors to use the CardioMap device in end markets such as hospitals, doctors’ offices, rehabilitation centers and sports medicine practices.
  • Save-A-Life (SAL) is a patented, single-action, instantaneous, handheld, mechanical anti-choking device that creates a vacuum chamber in the mouth to dislodge throat obstructions in a matter of seconds, all without harm to the victim. The device is currently in development, with a proof of concept established.
    • Odyssey believes that, once FDA-approved, its anti-choking device will quickly become the “accepted” standard and leader in the treatment of choking incidents globally. Its low-cost manufacturing and convenient portable design give SAL a competitive edge over competing devices utilizing cumbersome masks.

Market Opportunities

Odyssey’s varied development pipeline positions it to address a number of sizable market opportunities with significant unmet medical need. Concussions alone currently account for medical costs of roughly $10-15 billion annually in the U.S., despite the lack of a currently approved FDA drug treatment. This need is particularly apparent in the military and sports industry, where the likelihood of athlete head-injury recurrence is estimated at 75%.

It is for this reason that, in March 2021, Odyssey announced the formation of a sports advisory board featuring well-known athletes supporting the company’s efforts to enhance public awareness of traumatic brain injuries and concussions, as well as the need for an FDA-approved therapy. Members of Odyssey’s sports advisory board include NFL Hall of Famers Kurt Warner & Brett Favre and two-time Olympic gold medalist Abby Wambach.

With its CardioMap platform, Odyssey is targeting the global cardiac monitoring market, which was valued at $28 billion in 2021 by Insight Partners and forecast to reach $43 billion by 2028.

Save-A-Life targets a similarly underserved market. Choking is the fourth-leading cause of death in children, and approximately 5,000 choking deaths occur each year in the U.S. While 95% of these deaths result from in-home incidents, current choking rescue devices fail to address in-home applications.

Management Team

Joseph Michael Redmond is the President, CEO and Chairman of Odyssey. He has over 30 years of commercial experience in medical device companies, previously serving as CEO of Parallax Health Sciences Inc., V.P. of Business Development for DxTech Inc. and V.P. of Sales and Marketing for Bioject Medical Technologies Inc. While at Bioject, Mr. Redmond helped raise over $15 million in capital, entered into several licensing and distribution deals with major biotech and pharmaceutical companies and grew the market cap of the company from under $10 million to over $400 million. He started his career at Abbott Labs and holds a B.A. from Denison University.

Christine M. Farrell is the company’s CFO and Secretary. Prior to joining Odyssey, Ms. Farrell was Vice President of Finance for Bioject Medical Technologies Inc. She also held accounting and financial management positions with Spar-Tek Industries, a manufacturer of high quality and cutting-edge technology for the plywood industry, and Action Machinery, a seller of new and used robotic machine tools and equipment. Ms. Farrell holds a B.A. in Accounting from the University of Washington and an M.B.A. from Willamette University.

Dr. Jacob W. Vanlandingham is Odyssey’s Head of Drug Development. Dr. Vanlandingham holds a Ph.D. in neuroscience with a molecular biology focus. He is a member of the Society for Neuroscience, American Society for Nutritional Sciences, National Neurotrauma Society, Faculty for Undergraduate Research in Neuroscience and the International Association of Medical Science Educators.

Odyssey Group International Inc. (OTC: ODYY), closed Thursday's trading session at $0.1799, up 2.3904%, on 111,970 volume. The average volume for the last 3 months is 111,970 and the stock's 52-week low/high is $0.11/$0.64.

Recent News

Silo Pharma Inc. (OTCQB: SILO)

The QualityStocks Daily Newsletter would like to spotlight Silo Pharma Inc. (OTCQB: SILO).

Silo Pharma (OTCQB: SILO) recently announced it had produced an initial batch of SPU-21 liposomes for a rheumatoid arthritis study conducted by Frontage Laboratories, a contract research organization (“CRO”). “Recent research by the company revealed that SPU-21 liposomes have the ability to target inflamed epithelium, suggesting they can be used to target drug delivery. Further, SPU-21 can potentially be used to develop fusion imaging molecules and/or nanoparticles to study arthritic pathogenesis. According to the research, this approach may enhance therapeutic effects and decrease potential toxicity despite systemic administration of the drug,” a recent article reads. “In addition, Silo recently announced positive results in subcutaneous delivery of its novel liposomes to treat arthritic patients. This contrasts with previous animal research testing ART-1-Cy7 liposomes using intravenous injection, suggesting that subcutaneous administration possibly trends higher than intravenous injection with fewer toxic effects. ‘The successful results of our study show that the subcutaneous route of liposomal administration is well-suited for use in targeted drug delivery of anti-arthritic agents,’ said Silo Pharma CEO Eric Weisblum. ‘We suggest that this drug delivery approach would not only enhance efficacy but also reduce systemic toxicity.’” To view the full article, visit

As more research on the therapeutic benefits of psychedelics is conducted, concerns about whether microdosing works continue to grow, as many believe that the supposed benefits may be solely because of the placebo effect. It doesn’t help that data from placebo-controlled trials is inconclusive, which only means that the best way to find out whether microdosing is actually effective is to carry out properly controlled microdosing clinical trials. The following are a few of the ongoing microdosing clinical trials. Earlier in the year, Filament Health announced that it was launching a phase II psilocybin microdosing clinical trial in collaboration with the University of Toronto. The trial’s objective is to look into the use of psilocybin microdoses as treatment for persistent depressive disorder. The trial will involve 50 patients with depression, half of whom will receive a placebo while the other half will receive 2mg of psilocybin once a week for four weeks. If the trial finds that psilocybin microdosing is effective in treating depression, this will be good news for the more than 10% of individuals in America who are currently on antidepressants.  Selective serotonin reuptake inhibitors, which are usually prescribed as antidepressants, aren’t effective in most individuals with depression and often cause side effects. These trials are only a few of the ongoing or planned studies looking into the therapeutic effects of psychedelics. As companies such as Silo Pharma Inc. (OTCQB: SILO) press ahead with their drug development efforts, we will see more trials demonstrating the benefits or potential drawbacks of these novel pharmaceutical compounds.

Silo Pharma Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company, is focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as post-traumatic stress disorder (PTSD), fibromyalgia, Alzheimer’s disease, Parkinson’s disease, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund research that the company believes will be transformative to the wellbeing of patients and the health care industry.

Silo is committed to developing innovative solutions to address a variety of underserved conditions. Combining Silo’s resources with world-class medical research partners, the company looks to make significant advances in the medical and psychedelic space.

Silo works to identify and partner with leading medical universities, providing the needed financial resources to develop safe therapeutic treatments while moving cutting-edge research through the clinical stage and into commercialization. The company is well-capitalized with access to additional funds as opportunities present themselves.

Silo recently engaged Donohoe Advisory Associates LLC for consulting and advisory services in connection with the potential uplisting of Silo’s common shares to the Nasdaq Stock Market.


Silo has entered into research agreements and partnerships with multiple leading medical universities.

The company is involved in a sponsored study with Maastricht University utilizing repeated low doses of ketamine and psilocybin to examine the effects on cognitive and emotional dysfunctions in Parkinson’s disease and to understand its mechanism of action. The investigator in the Netherlands is acquiring the substances for the study and will then finalize the documentation to submit to the ethics committee.

Additionally, in June 2021, Silo announced its entry into a scientific research agreement with the University of California San Francisco (UCSF). The agreement will leverage four other clinical trials being planned by the university to determine the effects of psilocybin on inflammation. The study will take place at The Translational Psychedelic Research (TrPR) Program at UCSF.

Silo also recently extended its exclusive option agreement with the University of Maryland, Baltimore (UMB) to explore a novel invention generally known as joint-homing peptides. These peptides are being developed for use in the investigation and treatment of arthritogenic processes and can be used for enhanced targeting of therapeutic agents.

This agreement includes the study of two separate peptides. The first is an option and study for the treatment of arthritis. The second is a patented licensed peptide for the central nervous system, with an initial study for MS autoimmune diseases, in addition to rheumatoid arthritis. Animal studies are underway for both initial indications relating to the UMB agreement, with the potential for studies evaluating additional indications in the future.

Finally, Silo signed an agreement with Columbia University granting it an option to license certain assets currently under development, including an Alzheimer’s disease formulation targeting NDMARs and 5-HT4Rs, as well as a prophylactic treatment for stress-induced disorders and PTSD. Both candidates are currently being tested in mice and have already provided early data.

In addition to its university partnerships, Silo entered a joint venture agreement with Zylo Therapeutics Inc. (“ZTI”) focused on the development of ketamine and psilocybin using ZTI’s Z-Pod™ technology for the transdermal time released delivery of therapeutics. In November 2021, the company announced ZTI’s reception of its first ketamine shipment and initiation of loading ketamine into its Z-Pod technology. In a news release, Eric Weisblum, CEO of Silo, called the development an “important milestone” that will help the company “study the benefits of slow-release transdermal release of Ketamine.”

Market Overview

According to Coherent Market Insights, the fibromyalgia treatment market was valued at $2.78 billion in 2018 and has a projected CAGR of 3.3% over the forecast period 2018 to 2026. Fibromyalgia is a condition that causes pain all over the body, sleep problems, fatigue, and emotional and mental distress.

The global PTSD therapeutics market is expected to reach $10.68 billion by 2026 with a CAGR of 4.5% during the forecast period from 2018 to 2026, according to a report by Credence Research. Growing prevalence of PTSD is the chief factor driving the global treatment market. Increases in events such as wars, combat, and interpersonal violence has been a major contributing factor. Other factors like growing emphasis on rehabilitation initiatives by governments for treating their war veterans has also been facilitating the increase in demand for PTSD therapeutics.

Fortune Business Insights reports the global Parkinson’s disease treatment market is predicted to grow to $8.38 billion by 2026, with a CAGR of 8.1% during the forecast period. Parkinson’s is a neurodegenerative disease of the central nervous system which primarily affects the brain, causing uncontrollable shaking and tremors, difficulties in balance and restricted body movement making it difficult for the person to function or perform a daily routine.

Management Team

Eric Weisblum is CEO and founder of Silo Pharma. He has over 25 years of Wall Street experience, most recently in the biotechnology sector. He has served on the board of Aikido Pharma and was the president of Sableridge Capital. He has a proven track record in licensing therapeutic assets and assisting in their development. He brings to the company nearly 20 years of expertise in structuring and trading financial instruments. He holds a bachelor’s degree from the University of Hartford’s Barney School of Business.

Dr. Kevin Muñoz was appointed to the Silo board of directors in October 2020. He teaches biomedical sciences and medical intervention for the Passaic County Technical Institute. He previously served as Director of Operations at Physical Medicine and Rehabilitation. He began his career with Harlem Health Promotion Center in New York City as a research assistant. He earned a bachelor’s degree from the University of Michigan and a Doctor of Medicine from Xavier University School of Medicine.

Josh Woolley, M.D., Ph.D., is a Scientific Advisor for Silo. He is an associate professor in the Department of Psychiatry and Behavioral Sciences at the University of California, San Francisco. He is also a psychiatrist on staff at the San Francisco Veterans Affairs Medical Center. He is the director and founder of the Bonding and Attunement in Neuropsychiatric Disorders Laboratory. He received both his M.D. and his Ph.D. in Neuroscience from UCSF, where he completed his psychiatry residency training.

Charles Nemeroff, M.D., Ph.D., is a Scientific Advisor for Silo Pharma. He directs the Institute for Early Life Adversity Research within the Department of Psychiatry and Behavioral Sciences as part of the Mulva Clinic for the Neurosciences. He was chair of the Department of Psychiatry and Behavioral Sciences and clinical director of the Center on Aging at the University of Miami Miller School of Medicine. He received his M.D. and Ph.D. in neurobiology from the University of North Carolina School of Medicine.

Silo Pharma Inc. (OTCQB: SILO), closed Thursday's trading session at $0.14, up 6.0606%, on 5,910 volume. The average volume for the last 3 months is 5,910 and the stock's 52-week low/high is $0.0892/$0.2489.

Recent News

FuelPositive Corp. (TSX.V: NHHH) (OTC: NHHHF)

The QualityStocks Daily Newsletter would like to spotlight FuelPositive Corp. (NHHHF).

FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF), a Canadian-based, growth-stage company committed to providing commercially viable and sustainable, cradle-to-cradle, clean-energy solutions, has begun the validation of its onsite, containerized green ammonia production system — ahead of schedule; in addition, the company announced that it will start accepting presales on Aug. 10, 2022. According to the announcement, critical milestones, such as the hiring of key team members and a move to a new facility, have been met as the company has prepared for the launch of its first demonstration pilot project. In addition, the company implemented a process in which each component is individually tested as it is ready, which drastically reduced the time required for final validation, compensated for unexpected delays and allowed the validation process to begin earlier than planned. Consequently, the company anticipated validation to be completed internally by November 2022, with two independent, third-party validations following shortly after that. The company has announced a live webinar to provide a corporate update and answer questions. That webinar is scheduled for Aug. 9, 2022, at 2 p.m. ET. “We are moving along quickly towards getting our first demonstration system onto the farm, and we’ve been realizing the tremendous benefits of having such an experienced and dedicated team to get us there,” said FuelPositive CEO and board chair Ian Clifford in the press release. “Our company is growing rapidly. Only a year ago, we set the groundwork for a successful business, and we now have a robust team of experts, advisors, multiple premises, respected partners, a patent-pending technology on the verge of being fully validated and presales starting up. It’s extremely gratifying to be achieving these milestones, doing what we said we would do to make a huge contribution to food security and positive environmental change around the world.” To view the webinar, visit To view the full press release, visit

FuelPositive Corp. (TSX.V: NHHH) (OTC: NHHHF) is a growth stage company focused on licensing, partnership and acquisition opportunities building upon various technological achievements. The company is committed to providing commercially viable and sustainable clean energy solutions, including carbon-free ammonia (NH3), for use across a broad spectrum of industries and applications.

FuelPositive is headquartered in Toronto, Canada.

Hydrogen Economy Problems and FuelPositive’s Carbon-Free Technology

The hydrogen economy is currently facing many challenges. Traditional NH3 manufacturing exists on a massive scale, but centralized facilities result in some of the world’s most concentrated CO2 emissions. In total, an estimated 200 million metric tonnes of NH3 are consumed each year, with greater than 80% utilized by the agricultural sector. NH3 is also being positioned as a viable alternative to fossil fuels.

FuelPositive’s flagship carbon-free ammonia technology provides an innovative solution to these environmental concerns. Developed by Dr. Ibrahim Dincer and his team, the company’s platform allows for the in-situ production of NH3 in an entirely sustainable manner, using only water, air and sustainable electricity.

The production of hydrogen is energy intensive, but it is just one variable hindering the growth of the hydrogen economy. Other hurdles include:

  • Storage – The storage of hydrogen by compression or liquification are both cost prohibitive and unsustainable.
  • Distribution – The distribution network for effective hydrogen deployment has yet to be developed, as the extreme high-pressure distribution requirements to transport hydrogen would result in enormous infrastructure costs.
  • End Use – R&D on the transportation-related end use applications for hydrogen is in its infancy, but almost any vehicle on the road today can be easily converted to run on NH3 at a considerably lower cost per mile traveled when compared to traditional fossil fuels.

A key benefit of FuelPositive’s patent-pending, first-of-its-kind carbon-free NH3 technology is its flexibility. The process allows for small, medium or large-scale production of NH3 on location, minimizing or even eliminating the challenges and volatility associated with storage and transportation to end use. As such, with an appropriately sized FuelPositive system and access to renewable energy, the end use applications for the company’s platform are nearly infinite.

Manufacturing Partnership

On May 19, 2021, FuelPositive announced its selection of National Compressed Air Canada Ltd. (“NCA”) to undertake manufacturing of the company’s Phase 2 hydrogen-ammonia synthesizer commercial prototype systems for carbon-free ammonia production.

In a news release detailing the partnership, FuelPositive CEO Ian Clifford noted, “This critical milestone for FuelPositive will confirm the broad application potential for our technology and is the backbone of our Carbon-Free Hydrogen-NH3 offering. Partnering with the knowledgeable and experienced team at NCA on this commercialization project will bring our development-stage program to life.”

Global Ammonia Market Outlook

The global ammonia market was valued at $52.71 billion in 2017 and is forecast to reach $81.42 billion by 2025, growing at a CAGR of 5.59%, according to data from Fior Markets (

The agricultural industry consumes more than 80% of global NH3. Smaller percentages can be attributed to the waste, water treatment, refrigerants, antiseptic, textile, mining and pharmaceutical industries.

One of the most polluting industries on the planet consists of conventional agribusinesses. These polluters are responsible for more greenhouse emissions per year than transportation. This is where FuelPositive’s technology is expected to be extremely beneficial.

Management Team

Ian Clifford is Director, CEO and Founder of FuelPositive Corp. He has over 25 years of experience in the fields of technology and marketing and has successfully led the company to global brand recognition through its unique energy solutions. Since 2006, Mr. Clifford has raised over $50 million in equity financing for FuelPositive. He also co-founded digIT Interactive, a full-service internet marketing company serving Fortune 500 clients, which he sold at the peak of the market in 2000.

Greg Gooch serves as a Director and President of FuelPositive. His multifaceted career in the electronics and finance industries has positioned him as a key advisor and funding partner to start-ups and new technology companies for over 40 years. Mr. Gooch has been involved with FuelPositive since its early days and has remained a significant supporter and consultant to the company over the years. He has a bachelor’s from McGill University and an MBA from the University of Western Ontario.

Dr. Ibrahim Dincer is a scientific advisor to FuelPositive and is recognized as a pioneer and international leader in the area of sustainable energy technologies. Along with his team, Dr. Dincer invented the modular carbon-free ammonia (NH3) production technology that FuelPositive is commercializing. His area of specialty covers various topics including ammonia, hydrogen energy and fuel cells; renewable energy systems; energy storage systems and applications; carbon capturing technologies, and integrated and hybrid energy systems He is currently managing an exemplary team of researchers in this commercialization project.

Marek Warunkiewicz is the company’s Communications & Branding Specialist. He brings more than 40 years of entrepreneurial expertise to the FuelPositive team, having held marketing, branding, advertising, project management and graphic design positions with various companies. Mr. Warunkiewicz has successfully created business-to-business marketing and advertising campaigns for a diverse group of clients ranging from high-tech to agriculture. He co-founded digIT Interactive and ZENN Motor Company alongside Ian Clifford.

Luna Clifford is the Director of Communications for FuelPositive. She has over 10 years of experience as a business owner and advisor, helping build and operate several successful start-up enterprises while managing complex stakeholder relationships. Ms. Clifford excels in strategic planning and team building, and she has completed extensive studies in the fields of communications and health care.

FuelPositive Corp. (NHHHF), closed Thursday's trading session at $0.1325, up 5.7462%, on 556,606 volume. The average volume for the last 3 months is 556,606 and the stock's 52-week low/high is $0.09/$0.24.

Recent News

Playgon Games Inc. (TSX.V: DEAL) (OTCQB: PLGNF)

The QualityStocks Daily Newsletter would like to spotlight Playgon Games Inc. (TSX.V: DEAL) (OTCQB: PLGNF).

Playgon Games (TSX.V: DEAL) (OTCQB: PLGNF) (FSE: 7CR), a propriety SaaS technology company delivering mobile live-dealer technology to online gaming operators globally, has reached a corporate milestone. According to the company, its player activity continues to scale at the company's live dealer tables, and in July Playgon surpassed $82 million in player betting turnover, or more than $2.6 million per day. The company noted that this is a corporate best since it launched in May 2021. In addition, Playgon reported record monthly and daily bet spots, or wagers, of $2.85 million and $92,100 respectfully at the its VegasLounge(TM) tables. “We have kicked off our third quarter with a record month in player activity,” said Playgon Games president and CEO Darcy Krogh in the press release. “We continue to see strong user engagement and traction in both organic and new business and are delighted our mobile live dealer offering is being well received. We have every reason to expect this to continue and grow monthly. . . . We are excited for the remainder of 2022 as we will announce new clients and 11 new markets in due course which should contribute meaningfully to our growth.” To view the full press release, visit

Playgon Games Inc. (TSX.V: DEAL) (OTCQB: PLGNF) is a SaaS technology company focused on developing and licensing digital content for the growing global iGaming market. The company provides a multi-tenant gateway that allows online operators the ability to offer their customers innovative iGaming software solutions. Its current software platform includes Live Dealer Casino, E-Table Games and Daily Fantasy Sports. Seamless integration at the operator level allows customer access without requiring the sharing of any sensitive customer data. Playgon games run on any browser and any device as fast and secure as a native app, without requiring any app store download. All that’s needed is a stable internet connection. The gaming experience is identical across all mobile devices. As a true business-to-business digital content provider, the company’s products are scalable turnkey solutions for online casinos, sportsbook operators, location-based operators, media groups, and big database companies.

Playgon’s proprietary technology provides digital games for online gambling sites and mobile device apps, with the company licensing its mobile live-dealer technology to online gaming operators worldwide. Playgon combines high definition live streaming dealers with state-of-the-art augmented reality betting to provide the most authentic casino experience, live from Las Vegas. Playgon’s mobile platform features popular table games, all optimized for one-handed play on mobile devices.

The COVID-19 pandemic has accelerated an already existing shift away from location-based casinos to online gambling. At the same time, the proliferation of mobile devices has provided players with new access to betting. A younger, tech-savvy consumer demographic is driving adoption of digital gaming globally. To meet this demand, Playgon has launched a studio with 10 gaming tables from which its live dealer streaming video originates. The company’s platform is live with multiple online casino operators through four aggregator clients in South Africa and Europe, and commitments are coming in from more.

Playgon plans to expand the studio to 25 tables in the near term and is working to establish a U.S. strategy. The company will continue to expand licensing of its live dealer games to iGaming operators worldwide under a SaaS license agreement. As a B2B software supplier, Playgon avoids player acquisition costs.


Live Dealer Casino

Playgon offers the first and only Live Dealer Casino streaming live from Las Vegas. The company brings cutting-edge handheld features and functionality to the mobile generation of gaming enthusiasts who demand a world-class gaming experience on all devices. Playgon’s Blackjack delivers the look and feel of location-based casino tables with features providing players with the most unique user experience. The company’s true-to-life Roulette offers players a clear and uninterrupted view of the dealer, wheel, ball, bets, results, trends and statistics. Players can strategize, place multiple bets, track results and review trends without ever losing focus of the game.

Playgon’s traditional Baccarat and proprietary Tiger Bonus Baccarat™ prove their worth by not only recognizing the need for a prominent product, but by adding elements which separate them from the pack without removing their authenticity. The games mix advances in technology with the traditional game attributes that have resonated and captivated players for hundreds of years.

eTable Games

To lead the rise of mobile-first gaming, Playgon developed a user experience perfected for one-handed play. Providing this next evolution in gaming technology ensures the company’s client operators loyalty from existing customers and is a powerful strategy to attract and retain new players. Playgon’s VEGAS LOUNGE™ brings together an innovative mix of games, technology and gameplay that offers players an authentic experience and real Las Vegas casino fun every time, everywhere.

Daily Fantasy Sports

Playgon’s Daily Fantasy Sports (DFS) are a subset of fantasy sport games which typically target a younger demographic. DFS provides iGaming operators a turnkey fantasy sports platform that can quickly go to market, integrate with the operator’s existing operations and services, and be customized to match and enhance the operator’s brand. The platform is mobile and desktop friendly, built for regulated market environments, and allows operators to monetize users through a network of shared liquidity.

Market Outlook

Online casinos and sports betting sites/apps are increasingly adding market share to traditional location-based casinos. This trend is only expected to accelerate as millennials reach their peak earning years and Gen Z youth begin to complete their education and move into careers. These generations are completely comfortable with online recreation, as well as tech like digital wallets and digital gameplay that underpins Playgon Games. The company has been described as “Netflix + Vegas, all in one.”

The online gambling market is slated to reach a value of $127.3 billion by 2027, according to Grand View Research, with much of the growth expected from the U.S. and Asia. Even Europe, the most mature gaming market, is expected to grow at a rate of 20-25 percent year over year. The current global online Live Casino TAM is estimated at about $6 billion annually, and revenue is forecast to reach more than $8 billion by 2023 and more than $13 billion by 2027.

Management Team

Darcy Krogh is CEO of Playgon Games. He is a veteran of the iGaming industry with over 20 years of experience. In 1999, he co-founded Chartwell Technology Inc., which pioneered the development of browser-based digital content for the iGaming industry. After that company was sold to Amaya Gaming Group, he served as VP Business Development with Amaya. In 2016, he started Playgon Games (formally Global Daily Fantasy Sports Inc.) as President and CEO. His experience in the online gaming industry includes sales and marketing, relationship management, corporate finance, M&A, and strategic corporate development.

Guido Ganschow is President of Playgon Interactive. He has more than 12 years of experience in creating real-time Live Dealer technology and platforms and was the co-founder and Creative Director for a Macau-based casino consortium. Between 2008 and 2014, he successfully created and established Live Dealer platform businesses in Asia and Europe, and executed commercial partnerships, sales, and integration of the Live Dealer solution with major global gaming brands, including Ho Gaming Group, Chartwell Technology and Amaya Gaming Group.

Steve Baker is COO of Playgon. He is a former VP Operations for Shaw Communications, where he was directly involved in video streaming, home entertainment, new products, sales and M&A. He oversaw revenue growth from $300 million to $2.8 billion and employee growth from 350 to 13,000. He has broad experience and a proven record in development and implementation of cost effective and efficient growth strategies transitioning businesses from development to operations.

Harry Nijjar is CFO of Playgon Games. He is currently a Managing Director with Malaspina Consultants Inc. and provides CFO and strategic financial advisory services to his clients across many industries. This experience has allowed him to help his clients successfully navigate the regulatory and financial environments within which they operate. Mr. Nijjar holds a CPA-CMA designation from the Chartered Professional Accountants of British Columbia.

Playgon Games Inc. (PLGNF), closed Thursday's trading session at $0.04425, up 22.9167%, on 124,600 volume. The average volume for the last 3 months is 124,600 and the stock's 52-week low/high is $0.0299/$0.406.

Recent News


The QualityStocks Daily Newsletter would like to spotlight SPYR Inc. (OTCQB: SPYR).

SPYR (OTCQB: SPYR), dba SPYR Technologies, a diversified technology company developing products and leveraging the Internet of Things (“Iot”) for consumer use and large-scale applications and industries, and its subsidiary GeoTraq has completed a full suite of Mobile IoT asset management tools. The suite is designed to create significant return on investment (“ROI”) for enterprise customers in most industry verticals. According to the announcement, GeoTraq’s ultra-small tracker enables customers to deploy smart, connected technological accounting and monitoring devices within the IoT; the tracker features a proprietary blend of affordability, compatibility and efficiency offered under the GeoTraq label. According to the company, GeoTraq is the most robust suite of Mobile IoT Modules for Asset Tracking. Essentially, vehicles, parts, boxes, pallets, people, equipment, furniture and more can now be tracked globally through GeoTraq Mobile IoT modules. “GeoTraq is now well-positioned to drastically change the ways companies are viewing Asset Management,” said GeoTraq chief technology officer Pierre Parent in the press release. “As we significantly reduce the size and cost of our Tracker modules, the universe of assets that will be tracked grows simultaneously and exponentially. . . . Entirely new categories of assets will be tagged that are lower in value and size and we are already working with companies on disposable tracking tags that will be discarded along with the packaging and wrappers. Frankly, this level of scalable, easily integrated system is revolutionary." To view the full press release, visit

SPYR Inc. (OTCQB: SPYR), dba SPYR Technologies, is a technology company which, through its Applied MagiX Inc. subsidiary, develops and resells Apple®-ecosystem-compatible products with an emphasis on the growing, multibillion-dollar Internet of Things (IoT) Smart Home and Connected Car markets.

SPYR continues to identify and target acquisitions with an aim of growing its footprint in the industry and expanding the products it offers consumers, including companies developing artificial intelligence and smart-technology products. In 2020, SPYR acquired Applied MagiX Inc., a registered Apple developer and reseller of Apple ecosystem compatible products with an emphasis on the smart home market, as a wholly owned subsidiary. Applied MagiX operates in the IoT market and, more specifically, the segment of the market related to the development, manufacture and sale of devices and accessories specifically built on Apple’s HomeKit® framework. These products work within the Apple HomeKit ecosystem and are exclusive to the Apple market and its consumers.

Initially, while working to develop, manufacture and sell its own line of branded products, Applied MagiX will be sourcing HomeKit products and accessories from worldwide manufacturers, vetting and selecting best-of-breed products, selling them directly to consumers and supporting them. The company focuses on Apple consumers – a target market with higher disposable income and a demonstrated willingness to pay a premium for quality products. On average, Apple product users spend roughly twice as much on technology as other smartphone users. Those who purchase smart home products spend more than $3,000 on average.

By creating smart hardware and software solutions exclusively for Apple consumers, SPYR addresses a problem faced by that market – having few “smart” devices that integrate with Apple’s HomeKit, despite being the most affluent and loyal consumers of tech products.


The company’s Applied MagiX subsidiary offers multiple product lines to its target markets. First, the subsidiary is a reseller of third-party manufactured Apple HomeKit and Apple CarPlay compatible products. HomeKit comes pre-installed on every new iPhone, while the CarPlay platform is licensed by all major auto manufacturers. Applied MagiX identifies white label products, applies the company’s branding, improves the software and sells these improved products to consumers. Finally, Applied MagiX is developing its own proprietary line of smart home and connected car products, including Apple-compatible home cameras, sensors and alarms, as well as additional Apple-compatible smart car products in the iOS ecosystem.

Among the subsidiary’s products sold to consumers are:

  • The MagixDrive Wireless CarPlay adapter, which allows users to access CarPlay wirelessly using their iPhones
  • The HomeKit Secure Video Camera with iCloud Storage
  • The Multipurpose Sensor with Alarm
  • The Environment and Motion Sensor
  • The Window and Door Contact Sensor

Market Outlook

According to Statista, the global smart home market is expected to generate revenue of more than $104 billion in 2021. The market is forecast to hit more than $187 billion in revenue by 2025, recording a CAGR of 15.75 percent.

The number of active households in the worldwide smart home market is expected to reach nearly 500 million by 2025. Household penetration is just over 12 percent in 2021 and is projected to nearly double by 2025 to more than 22 percent.

Allied Market Research valued the global connected car market at more than $63 billion in 2019 and projected a CAGR of 17.1 percent, which would push revenue to more than $225 billion by 2027. Allied identified rising consumer demand for connectivity solutions, surging need for constant connectivity, increasing dependency on technology and an upsurge in tech-savvy population as key factors driving the projected growth of the connected car market.

Management Team

James R. Thompson is the CEO, President and General Counsel of SPYR. Over the past 28 years, Mr. Thompson has deftly managed a colorful spectrum of legal clients and situations. In the process, he has helped many companies – both large and small – thrive. Now he welcomes the challenge to take the company and his career in an entirely new direction. A native of Philadelphia, he holds a J.D. from Rutgers University and a Bachelor of Science from the University of Denver.

Jennifer Duettra is the Executive Vice President of SPYR. She brings a great deal of knowledge in mobile gaming and pop culture to the company. She is an attorney and was thrilled by the prospect to combine her law experience with a chance to be creative. She is a native of Colorado and received her Bachelor of Arts in Political Science and Speech Communication from Colorado State University. She holds a J.D. from Harvard University.

Trang Nguyen is the CFO of SPYR. From 2019 to 2020, she served as the Financial Reporting Manager for Del Taco, where she was responsible for the preparation and filing of periodic financial reports with the U.S. Securities and Exchange Commission. From 2016 through 2019, Ms. Nguyen was Accounting Manager for Pinnacle Tax Accounting in Los Angeles, California. She was a part of Ernst & Young’s audit team in Los Angeles from 2006 to 2008, leading engagements on interim and year-end ad SOX 404 auditing procedures for major enterprise accounts. Ms. Nguyen holds a Bachelor of Art, Business Economics (Minor in Accounting) from the University of California, Los Angeles. She is a certified public accountant with an inactive license.

Dr. Harald Zink is the CEO, Founder and Chief Product Architect of SPYR subsidiary Applied MagiX. Prior to founding Applied MagiX, he was Director of Technologies and later Vice President of Technologies at Sarkissian Productions in Los Angeles. He also served as Director of Technologies at SMZ Technologies and, for more than 17 years, as Macintosh Technology Consultant to The Walt Disney Studios in Burbank, California. He speaks five languages and holds degrees from the University of California, Riverside.

Kelly Clark is the COO of Applied MagiX. Before joining the subsidiary, he worked as Vice President of Sales Operations at TruClear Global. Prior to that, Mr. Clark was Senior Director of Program Management at Pacific Group Ventures and Operations Manager at Barco. He has also held operations management positions at Deluxe Digital Studios and Sony Pictures Entertainment. Mr. Clark holds a bachelor’s degree in international business from the University of Southern California.

SPYR Inc. (OTCQB: SPYR), closed Thursday's trading session at $0.032, up 52.381%, on 1,528,249 volume. The average volume for the last 3 months is 1.528M and the stock's 52-week low/high is $0.0132/$0.0977.

Recent News

Correlate Infrastructure Partners Inc. (OTCQB: CIPI)

The QualityStocks Daily Newsletter would like to spotlight Correlate Infrastructure Partners Inc. (OTCQB: CIPI).

Correlate Infrastructure Partners (OTCQB: CIPI) is a purpose-built energy use optimization company based in the United States. CIPI has made it its mission to develop green utility solutions for the commercial real estate industry to enable buildings and other corporate facilities to help contribute to a climate solution. “The company works to provide advisory assistance on acquisitions and project development to commercial solar industry clients and to back that up with development and financing resources for commercial clients looking for clean energy facility upgrades. CIPI’s subsidiaries, Correlate and Solar Site Design, use data analysis and a commitment to transparency to help their clients achieve clean energy solutions,” a recent article reads. “The path to full decarbonization will take ambition and intentional execution,” CIPI CEO Todd Michaels said, signaling the need for businesses to not only establish plans but execute on them. “By teaming up with industry innovators and experts, we can guide commercial real estate owners in creating new revenue and rent opportunities from their existing energy assets.” To view the full article, visit

Correlate Infrastructure Partners Inc. (OTCQB: CIPI), formerly Triccar Inc., through its two subsidiaries, Correlate and Solar Site Design, offers a complete suite of proprietary clean energy assessment and fulfilment solutions for the commercial real estate industry. The company believes scaling distributed clean energy solutions is critical in mitigating the effects of climate change. CIPI is at the forefront in creating an industry-leading energy solution and financing platform for the commercial and industrial sector. The company sees tremendous market opportunity in reducing site-specific energy consumption and deploying clean energy generation and energy efficiency solutions at scale.

The opportunity exists to remove friction between today’s legacy finance process and the needed clean-energy upgrades developed within the company’s program technologies. For the U.S. to reach its 2050 carbon goals, 200,000 commercial buildings must be retrofitted every year until that date. That represents approximately a 5-10x increase over the 2022 industry process run rate.

CIPI announced completion of its acquisition of 100% of the equity of Correlate Inc. and Loyal Enterprises LLC dba Solar Site Design on December 28, 2021. The company notes these acquisitions occurred at a key inflection point of its growth. CIPI currently enjoys channel and sales partnerships with Fortune 250 companies and a strong, proven industry network.

The company’s transparent, leading-edge model changes value delivery for both facility owners and proven solution providers seeking scale. CIPI believes its rapid growth is due to industry demand for actionable, cashflow positive energy programs and the underlying carbon reduction mandates taking effect globally.

CIPI has filed with the SEC for a name change to Correlate Infrastructure Partners Inc., which will more closely reflect its new platform and growth focus. The company has been aggressively moving to rebrand, with efforts including a revised website, investor presentation materials and an investor relations awareness campaign. The company’s shares will continue to trade on the OTCQB Venture Market under the current ‘CIPI’ ticker symbol until changes are approved.


Correlate, founded in 2015, is a portfolio-scale development and finance platform offering commercial and industrial facilities access to clean electrification solutions focused on locally-sited solar, energy storage, EV infrastructure, and intelligent efficiency measures. Its unique data-driven approach is powered by proprietary analytics, concierge subscription services, and a highly scalable national fulfillment network to help building owners profit from fully funded, turnkey decarbonization and facility health programs. The platform is designed for commercial and industrial real estate owners seeking to significantly improve net operating income while meeting carbon reduction goals. The platform provides energy programs for commercial property portfolios and requires no upfront capital. Client organizations reduce their risk and generate more profits by leveraging Correlate’s unique payment programs to put more cash in the bank. Deploying Correlate’s strategic energy programs and energy management systems allows property-owning organizations to complete big energy changes across their portfolios.

Solar Site Design, founded in 2013, is a U.S. Department of Energy Sunshot Catalyst winner that provides customer acquisition and project development tools for the commercial solar industry. Its commercial marketplace platform connects highly qualified project opportunities to leading solar construction companies nationwide. The Solar Site Design platform gives commercial and industrial property owners access to the best price for a commercial solar system. Commercial solar analysts provide property owners a site assessment and working project proposal. Solar Site Design’s team of solar engineers finalize the design while approved financing providers help clients explore financing options for their projects. Then, approved contractors in Solar Site Design’s Marketplace bid on the projects, ensuring commercial and industrial property owners get the best estimates for their projects. Solar Site Design’s marketplace process promotes transparency and fair pricing. Its team of experts has nearly 20 years of experience in the solar industry. Only reputable, experienced, certified (NABCEP), licensed, bonded and insured contractors are accepted into the Solar Site Design Marketplace.

Market Outlook

CIPI is in a rapidly growing market with a unique offering to address a total market of more than 5.9 million commercial buildings in the United States, according to the U.S. Energy Information Administration. Currently, the company’s wholly owned subsidiaries, Correlate and the Solar Site Design, have an opportunity pipeline of over $100 million in commercial projects with more than $20 million in awarded backlog. According to the Rocky Mountain Institute, portfolio energy optimization is a $290 billion market in the United States driving deep financial savings and energy efficiency across the commercial sector.

Commercial buildings consume more than 35% of the generated electricity in the U.S. and are underperforming in energy efficiency at every level. These buildings waste energy, emit too much carbon, and are too costly for owners and occupants, but retrofits are not happening at the rate or scale needed.

In today’s real estate market, portfolio property owners own most commercial buildings. Yet most building efficiency work is focused on single buildings, thereby missing the distinct needs of this owner class which has very different needs than traditional owner-occupiers. The diverse nature of commercial buildings, combined with technology and performance uncertainty, make simple energy optimization initiatives – which could greatly reduce energy use and improve building value – financially unattractive, resulting in slow adoption rates. CIPI’s financial instruments and software breakdown this issue known as the “split incentive”, unlocking the majority of the addressable market.

Management Team

CIPI has in place a nationally recognized management team that has been active in the energy market since 2005.

Todd Michaels is President and CEO of CIPI and founder of Correlate. He formerly served as Vice President for Innovation at SunEdison and Senior Director Distributed Solar at NRG Energy. He founded Correlate in 2015 and has 16 years of experience in the energy industry. He graduated from Indiana University with a B.S. in Computer Information Systems.

Channing Chen is CFO at CIPI and Correlate Inc. and brings over 16 years of experience in the solar industry as a developer, financier, and business unit leader. He has held executive management roles at Solar Power Partners (acquired by NRG Energy), where he was a founding employee, SunEdison, and NRG Energy (NYSE: NRG). Most recently, Mr. Chen was founder and Managing Partner at Breakaway Energy Partners LLC – a distributed energy financing and market-making platform. To date, Mr. Chen and his teams have raised over $1.5 billion in financing across residential, commercial, and utility scale solar and energy storage projects representing over 400 MWs. He holds a B.A. in Environmental Chemistry from the University of California at San Diego and an MBA from the University of Southern California. He is also an advisor and early-stage investor to several startup companies in the renewable energy space.

David Bailey is Chief Revenue Officer of Correlate Inc. With over 15 years of executive sales, supply chain management, and energy efficiency experience, he is responsible for ensuring the success of the National Commercial Sales Unit across multiple regional project teams. Mr. Bailey created and launched the Transformation Services team while at Wesco for its multibillion-dollar Distributed Energy Resource division, formerly Westinghouse. His focus was on IoT-enabled efficiency and plant floor automation-based services. Before that, he spent several years in Global Account Sales Management, with GE Supply as a Program Manager, and is a Commercial Leadership Program graduate. Mr. Bailey received his B.S. in Mechanical Engineering from the University of Kentucky.

Jason Loyet is VP of Commercial Sales of Correlate Inc. He is a cleantech executive with over 20 years of experience leading high growth solar energy and software start-ups. Mr. Loyet is a U.S. Department of Energy SunShot Catalyst award winner for his work building the Solar Site Design technology platform. Before joining the solar energy industry in 2005, he founded and sold two software companies in the streaming media (GlobalStreams) and newspaper publishing (MyCapture) industries. Mr. Loyet currently serves as a Member of the Board of Directors for the Tennessee Solar Energy Industry Association (TenneSEIA).

Deke Welling is Head of Project Development and Fulfillment Services at Correlate Inc. He has over 19 years’ experience in the energy industry with an emphasis on renewables and energy efficiency over the past seven years. Prior to entering the renewables sector, Mr. Welling was the CEO of Welling Resources, an energy development company focused on the exploration of oil and natural gas reserves in the U.S. It was this experience that led him into the renewables sector and leading a charge for more sustainable resources. Additionally, Mr. Welling also served as the CEO of Circle L Solar Inc., a top 100 solar installer in the United States since 2016. Through his leadership, Circle L Solar experienced a growth rate of over 2,250% from 2016 to 2019, resulting in his company being listed on the Inc. 5000 list of the fastest growing private companies in the U.S. (Rank #176) and being named ‘Top Energy Company’ and ‘Entrepreneur of Year for the Energy Industry’ by the American Business Awards® in 2019 and again for ‘Entrepreneur of the Year’ in 2021.

Kevin Warren is Head of Construction and Development Engineering at Correlate Inc. He is a solar veteran with over 12 years of experience in the field. Prior to co-founding CLS, Mr. Warren was the owner of Beacon Consulting and has originated, consulted, designed and/or engineered over 122 MW of PV installations ranging from small commercial to utility scale projects throughout Texas, California, Colorado and North Carolina. He holds a Photovoltaic Technical Sales Professional Certification from the North American Board of Certified Energy Practitioners and certifications from Solar Energy International in PV Installation, PV Technical Sales, PV battery-based design, PV design and engineering, and PV operations and maintenance. Along with PV expertise, Mr. Warren is a LEED Green Building Associate, a certified building analyst from the Building Performance Institute, a Certified Renewable Energy Professional from the Association of Energy Engineers and holds a designation in High-Performance Sustainable Buildings from the BOMI Institute. He studied Electrical Engineering at the University of Texas at Arlington.

Tom Kunhardt is Director of Customer Success at Correlate. He previously held a similar position at Clean.Tech and was Corporate Trainer, Learning & Development, at NRG Energy. He has 15 years of experience in the solar and clean energy industries helping homeowners and businesses find solutions to their energy needs. He holds a bachelor’s degree from the University of Massachusetts.

Correlate Infrastructure Partners Inc. (OTCQB: CIPI), closed Thursday's trading session at $1.42, off by 0.699301%, on 3,100 volume. The average volume for the last 3 months is 3,100 and the stock's 52-week low/high is $0.3021/$3.25.

Recent News

Mullen Automotive Inc. (NASDAQ: MULN)

The QualityStocks Daily Newsletter would like to spotlight Mullen Automotive Inc. (MULN).

A reporter from CNN recently went on an EV road trip, which proved that insufficient charging infrastructure rather than small EV batteries and range anxiety is a major barrier to electric vehicle adoption. After traveling 950 miles across several states in an EV, the CNN reporter concluded that developing a network of convenient and reliable charging stations is the solution, rather than developing EVs with larger battery packs and more range. Peter Valdes-Dapena drove a Mercedes-Benz EQS 450+ from New York City to Atlanta, covering around 950 miles. Although the EQS has an estimated range of 350 miles on a single charge, Valdes-Dapena’s vehicle showed an estimated 446 miles on the internal display. The CNN reporter says that the actual range would be lower because he mostly drove on highways at high speeds, and he posits that he could have traveled around 370-390 miles on just one charge. Based on his experience driving the EV, Valdes-Dapena observed that America’s public EV charging infrastructure was far from perfect. More often than not, public chargers were defective or didn’t work at all. Furthermore, the scarcity of reliable chargers means that even if your navigation system listed a station as available, another driver could plug their car in just seconds before you arrive. With federal and state governments determined to improve the existing charging infrastructure, electric vehicle makers such as Mullen Automotive Inc. (NASDAQ: MULN) can look forward to better sales as the public notices that charging stations are springing up close to them and on the routes they take while traveling.

Mullen Automotive Inc. (NASDAQ: MULN) is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership.

Commencement of Trading on Nasdaq

On November 5, 2021, Mullen announced its commencement of trading on the Nasdaq Capital Market.

“Today is a monumental day for Mullen Automotive. I am especially proud of our team, investors and all who have believed in Mullen and taken us to this point as a publicly traded company on the Nasdaq Capital Market,” David Michery, CEO and Chairman of Mullen Automotive, stated in the news release. “Trading on Nasdaq now opens us up to new investors, both institutional and retail shareholders, and broadens our awareness and company profile, while increasing awareness of Mullen and our technology platform and opening new opportunities in EV and beyond. The road ahead has never been brighter for Mullen, and I am proud to lead us into the future.”

The milestone came in the wake of the company’s stock-for-stock merger with Net Element Inc.

The Mullen FIVE

The Mullen FIVE EV Crossover, debuting at the Los Angeles International Auto Show (LAIAS) on November 17, 2021, embodies Mullen’s Southern California roots with an inspired design focused on two complementary Golden State themes – California landscape and California urban.

The FIVE is built on an EV Crossover skateboard platform that offers multiple powertrain configurations and trim levels in a svelte design that is Strikingly Different™ and exciting to experience in person.

Prior to the start of LAIAS, the Mullen FIVE was selected as a finalist by the LA Auto Show for Top EV SUV in the ZEVA “People’s Choice” Awards.

LAIAS provides Mullen an opportunity to display multiple variants of the FIVE model while also showcasing its powertrain, battery and charging technology. The company intends to bring the FIVE to market in 2024, and reservations are currently open here.

Mullen’s development portfolio also includes EV Fleet Vans, which it intends to bring to market in Q2 2022, and the pure electric, high performance Mullen DragonFLY.

Expansion of Manufacturing Capacity

On November 2, 2021, Mullen announced plans to expand its facility in Robinsonville, Mississippi.

Mullen’s Advanced Manufacturing and Engineering Facility (AMEC) currently occupies 124,000 square feet of manufacturing space. The total available land on the property is over 100 acres, and Mullen is moving ahead with plans to build out another 1.2 million square feet of manufacturing space to support class 1 and class 2 EV cargo vans and the Mullen FIVE EV Crossover.

On the expanded site, Mullen plans to build a body shop, a fully automated paint shop and a general assembly shop.

EV Market Outlook

The global EV market was reported to consist of 3,269,671 units in 2019, a figure that is expected to grow at a CAGR of 21.1% through 2030 to a total of 26,951,318 units worldwide. This market’s monetary value was estimated at $162.34 billion in 2019 and is expected to grow at a CAGR of 22.6%, resulting in an approximate value of $802.81 billion by 2027. The primary driver for this exponential growth is a worldwide increase in vehicle emissions regulations.

Management Team

David Michery is the CEO and Founder of Mullen and has been leading the company and its divisions since inception in 2014. With over 25 years of executive management, marketing, distressed assets, and business restructuring experience, Mr. Michery brings a wealth of relevant knowledge and expertise to the Mullen brand. He has notably created 12 trademarks so far to develop the company brand and vision.

Mr. Michery is working toward a sustainable future accessible to all by creating a suite of clean-energy electric vehicles at varied price points. With entirely U.S.-based manufacturing and operations, he is also determined to have Mullen Technologies play a role in shaping a self-sustaining local economy by creating more jobs in America.

Mr. Michery manages risks and company expectations as a pathway to success and has personally overseen several businesses that totaled over $1 billion in transactions. His key strength is the ability to be fiscally responsible and lead teams to complete projects on time and within budget. As a seasoned professional in this space, Mr. Michery has demonstrated skill in building businesses from the ground up and into successful entities that subsequently sold for hundreds of millions of dollars.

Mullen Automotive Inc. (MULN), closed Thursday's trading session at $0.8434, off by 8.634%, on 78,781,429 volume. The average volume for the last 3 months is 78.781M and the stock's 52-week low/high is $0.52/$15.90.

Recent News

Flora Growth Corp. (NASDAQ: FLGC)

The QualityStocks Daily Newsletter would like to spotlight Flora Growth Corp. (NASDAQ: FLGC).

Cannabis is one of the fastest-growing industries in America for good reason. Barely a decade old, the industry has generated billions of dollars in sales revenue, created hundreds of thousands of new employment opportunities and filled state coffers with billions in tax revenue. Other territories and countries are adopting cannabis reform and launching legal markets, and they are starting to cash in on the lucrative cannabis market. Thailand, which recently decriminalized the private cultivation of cannabis and sanctioned the use of cannabis leaves and extracts in foods, drinks and cosmetics, is beginning to rake in profits from the cannabis market. Consumer demand for cannabis products exploded as soon as the country lifted restrictions on cannabis, with Thai companies earning big bucks from the sale of products such as cannabis-infused skin-care products, bubble tea and desserts. Since recreational cannabis isn’t legal under Thai law, commercial cannabis products can only contain cannabidiol (CBD). Unlike THC, cannabidiol is not psychoactive and will not make users feel high. For products to be approved, they have to contain less than 0.2% THC. Charvirakul states that due to public health laws, recreational cannabis use isn’t permitted in the country. As more countries ease their restrictions on marijuana, companies with a transnational focus such as Flora Growth Corp (NASDAQ: FLGC) may have opportunities to spread their wings beyond the North American market.

Flora Growth Corp. (NASDAQ: FLGC) is an internationally focused cannabis brand builder that leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions, including cosmetics, hemp textiles, and food and beverage. Flora Growth operates one of the largest outdoor cultivation facilities in the world with an aim of marketing a higher-quality premium product at below-market prices. By prioritizing natural ingredients and value-chain sustainability across its portfolio, the company creates premium products that help consumers restore and thrive.

Flora Growth completed the first traditional cannabis IPO on Nasdaq in May 2021. Although currently headquartered in Toronto, Ontario, with plans to relocate its head office to Miami, Florida, the company’s base of operations is in Colombia, where it has built an extensive distribution network that includes Colombia’s largest distributors.

Currently, Flora Growth is organically growing market share for its existing brand portfolio (pharmaceuticals, textiles, cosmetics, and food & beverage) while seeking revenue-generating acquisitions that offer an accretive distribution network to amplify revenue growth.

Existing Brand & Product Portfolio

Flora Growth’s portfolio spans a number of verticals – each with a thoughtful brand designed to resonate with its intended end consumer. In line with the company’s mission, each brand prioritizes natural ingredients and value-chain sustainability.

Flora Lab S.A.S

Flora Lab is the company’s GMP certified manufacturing and R&D center focused on producing pharmaceuticals, cosmetics, and nutraceuticals for domestic and international markets. Its offerings include product lines that are private label, white-label, and custom formulas.

Through Flora Lab, Flora Growth has relationships with 1,500+ distribution channels, manufactures 63+ OTC products registered with INVIMA (Colombia National Food and Drug Surveillance Institute), and holds multiple GMP certifications enabling international export in an effort to leverage Flora Lab’s capacity to produce a wide range of CBD-infused products.

Flora Beauty

Flora Beauty is the company’s CBD beauty and cosmetics division founded by fashion and beauty industry icon Paulina Vega. Its current offerings include two CBD skincare brands targeting the U.S. and Latin American markets – MIND NATURALS and AWE. These lines exemplify Flora Growth’s socially conscious approach to business.

Currently, Flora Beauty products are offered globally through e-commerce, as well as through Falabella’s 111 retail locations across Latin America. The company is in negotiations with major department stores to launch the line in the U.S. and is also exploring opportunities in the U.K. and other European markets.

KASA Wholefoods

KASA Wholefoods is a Colombian manufacturer of food and beverages leveraging responsibly sourced exotic fruits from the Amazon. KASA has a $10 million+ distribution agreement with Tropi, Colombia’s largest food distributor, which has 130,000+ distribution points across the country.

Mambe, KASA’s leading brand, is already offered through over 980 distribution points across Colombia. Flora Growth expects this network to grow to over 1,200 distribution points in 2021, including one of Colombia’s largest coffee chains, Tostao Café & Pan.

Hemp Textiles & Co.

Through its Hemp Textiles division, Flora Growth intends to utilize its large land package and cultivation infrastructure to capture market share in the rapidly growing hemp industrials segment.

The company’s first brand through this division, Stardog Loungewear, offers a line of comfortable loungewear made from natural, organic materials. Stardog has been distributing globally through e-commerce and brick and mortar channels in Bogota since fall 2020, and the company intends to open U.S. brick and mortar locations in 2021.

Accretive M&A

Flora Growth is targeting transactions to complete the supply chain via key infrastructure to enhance its global distribution with the aim to compete on low-cost, high-quality inputs paired with premium brands that create business lines with robust margins.

To date, Flora has announced two major transactions.

Koch & Gsell (Acquisition)

  • Amplify CPG portfolio’s revenue growth through leading brand, Heimat, currently with TTM revenues of $7.6 million.
  • Leverage Koch &Gsell’s distribution network of 2,500+ stores to introduce Flora to the Swiss, European and Asian markets.
  • Bring patented hemp cigarette manufacturing technology into new markets utilizing Flora’s high-quality cannabis.

Hoshi International (Investment)

  • Equity Investment of €2 million into Hoshi to establish Flora as a preferred supplier to two EU processing facilities.
  • Opens gateway for Flora Growth’s cannabis through international distribution agreements in the EU and U.K.
  • Hoshi’s experienced team and increased access to the EU cannabis market to serve as a catalyst for revenue growth.


Key to Flora Growth’s expansion efforts is its cultivation strategy. The company’s Cosechemos farm, located in Bucaramanga, Colombia, is currently licensed to cultivate 247 acres of cannabis. Through three successful pilot crop plantings, the location has demonstrated a production cost of just $0.06/gram. For comparison, the average cost of North American cannabis (based on 2019 figures from Aphria, Tilray, Sundial, and Aurora) equates to roughly $1.89/gram.
Flora Growth is uniquely positioned to capitalize on Colombia’s favorable growing conditions, low-cost infrastructure, and affordable local workforce as it looks to ramp up its cultivation efforts moving forward.

Leadership Team

Bernard Wilson is the Chairman of Flora Growth. A senior financial professional, Dr. Wilson is the former Vice-Chairman of PricewaterhouseCoopers LLP and is the Chairman of the Founders Board of the Institute of Corporate Directors. He has also served as Chairman of the Canadian Chamber of Commerce; Chairman of the International Chamber of Commerce – Canada; and Member of the Canada/U.S. Trade Committee. Dr. Wilson draws on this experience to ensure Flora Growth adheres to effective corporate governance practices.

Luis Merchan is the company’s President and CEO. He is a proven executive with over a decade of experience in enterprise sales management, corporate strategy, merchandising and expense management, and customer experience. Mr. Merchan previously served as Macy’s Inc.’s Vice President of Workforce Strategy and Operations, where he managed the enterprise’s multi-billion-dollar P&L expense line for the entire 540 store portfolio. Throughout his tenure at Macy’s, he led various sales and marketing initiatives, including the B2B corporate sales team that was responsible for $160 million in annual revenue. Mr. Merchan obtained his Bachelor of Industrial Engineering from Pontifical Xaverian University in Bogota, Colombia, and his MBA from McNeese State University. He also holds a Graduate Certificate in Marketing Management from Harvard.

Juan Manuel Galan is a Strategic Advisor to the Flora Growth management team. Mr. Galan currently serves as a senior consultant to The World Bank. He is a politician and former senator of Colombia, serving three terms from 2006 to 2018 as a member of the Colombian Liberal Party. He is also a former professor at the University of Rosario and holds more than 20 years of journalistic, academic, governmental and parliamentary experience. During his time as a senator, Mr. Galan was a key leader, with 29 bills and 27 debates on political control, and 17 laws to his name. The most relevant of those laws was authoring the medical cannabis law that resulted in the legalization of medical cannabis in Colombia.

Stan Bharti is a Director of Flora Growth. Mr. Bharti currently serves as Executive Chairman of Forbes & Manhattan. He has more than 30 years of professional experience in business, finance, markets, operations and more, with a focus on the resource and technology sectors. To date, Mr. Bharti has amassed over $3 billion worth of investment capital for the companies with which he has worked and their shareholders. He is a Professional Mining Engineer and holds a master’s degree in engineering from Moscow, Russia, and University of London, England.

Javier Franco is the company’s VP of Agriculture. Mr. Franco is a master horticulturist with more than 25 years of experience in the design, implementation, and management of cultivation and propagation facilities of more than 30 species of cut flowers in Latin America. He completed his agricultural studies at Zamorano University in Honduras and later at an International Exchange Program at Ohio State University. Mr. Franco has directed technical, commercial, and research groups in the cut flower, fruit and vegetable markets in Latin America and has participated in the commercial development of new technologies applied in agribusiness. He has also led the agri-management of organic crops and certifications of Good Agricultural Practices.

Flora Growth Corp. (FLGC), closed Thursday's trading session at $0.7189, off by 2.8514%, on 511,799 volume. The average volume for the last 3 months is 499,285 and the stock's 52-week low/high is $0.586/$21.45.

Recent News

Eat Well Investment Group Inc. (CSE: EWG) (OTC: EWGFF)

The QualityStocks Daily Newsletter would like to spotlight Eat Well Investment Group Inc. (CSE: EWG) (OTC: EWGFF).

  • Eat Well’s goal of investing in the entire plant-based supply chain has seen it acquire Belle Pulses Ltd., Sapientia, and 51% of Amara Organic Foods
  • It has also seen the company invest in the CPG sector, food technology, agribusiness, and the media sectors in what the management describes as a strong foundation within its investment platform
  • The company recognizes the ongoing global supply chain challenges brought about by the COVID-19 pandemic, as well as the ongoing Russia-Ukraine war, as an opportunity to grow its market share and address an unfulfilled demand for its products
  • It maintains its 2022 revenue projections for its portfolio companies at $100 million, attributing it to the strong foundation it has laid down so far, as well as the aggressive push for its brand in the market

Since its inception, Eat Well Investment Group (CSE: EWG) (OTC: EWGFF) has remained committed to exploring and evaluating new investment opportunities in plant-based foods. Its operations have explored various sectors, including precision fermentation and regenerative agriculture, with the overall goal of investing in the entire plant-based supply chain in what it describes as a “seed-to-market” approach (

Eat Well Investment Group Inc. (CSE: EWG) (OTC: EWGFF), headquartered in Vancouver, British Columbia, is a publicly traded vertically integrated plant-based foods company combining the best of agribusiness, foodtech, and CPG brands to supply the world with innovative, delicious, and better-for-you foods. The company supplies Beyond Meat, Ingredion, Nestle, General Mills and more. It is on track to generate $60 million in revenue for 2021 and is projecting $100 million in revenue for 2022.

Eat Well’s management team has an extensive record of sourcing, financing and building successful companies across a broad range of industries and maintains a current investment mandate on the health and wellness industry. The team has financed and invested in early-stage venture companies for more than 25 years, resulting in the ability to construct a portfolio of opportunistic investments intended to generate superior risk-adjusted returns. Eat Well’s strategic advisory board includes pioneers in the plant-based foods industry, including HRH Prince Khaled bin Alwaleed bin Talal Al Saud, Founder and Chief Executive Officer of KBW Ventures, and Jeff Dunn, CEO of Bolthouse Farms who previously held senior leadership positions at both Campbell Soup Company and The Coca Cola Company.

The company’s plant-based investment thesis is centered on growing its seed-to-market operations, which include raw ingredients, processing, pulse fractionation, unique IP and premium consumer packaged goods (CPG). Eat Well Group is building a unique ecosystem that can supply these essential cornerstone needs for society. The company has plant-based foods and nutrition experts specializing in the latest science and original thinking for what consumers want most – high quality and affordability in healthy, clean and simple products.

Eat Well focuses on intellectual property, product portfolio development and long-term value creation for stakeholders in a rapidly expanding industry. As an emergent sector globally, plant-based foods represent a double-digit annual growth category, with more than 35% of the world’s supply of pulse proteins coming from Canada.


On July 31, 2021, Eat Well Group acquired Belle Pulses Ltd., one of the top pulse processors in Canada. Belle Pulses has been operating for over 40 years and had over $60 million in sales in 2020. The company counts a broad range of customers in over 35 countries, including global strategic food companies and major ingredient distributors. Currently, Belle produces nearly 100,000 tons of fully traceable seed and product, yielding over 26,000 tons of pure plant protein.

Eat Well also owns 100% of Sapientia Technology Inc. Led by Dr. Eugenio Bortone – one of the world’s preeminent food scientists and extrusion processing experts and the inventor of Frito-Lay’s Twisted Cheetos – Sapientia has filed four patents around the “protein curl” and crispy-puff-style snack. By focusing on texture and crunch, Sapientia’s patents solve one of the major problems that large scale snack food companies have struggled with for years – how to offer appealing texture and flavor in a guilt-free, not fried, natural and healthy alternative to the majority of snack food products available today.

Eat Well owns a 51% share of Amara Organic Foods, with an option to acquire additional ownership up to 80 percent. Amara, one of the fastest-growing baby food brands in America, is a food technology company that uses science and proprietary IP that locks in taste and texture to make healthy, organic, non-GMO, plant-based, convenient baby and children’s food possible for modern-day families. From baby food to toddler food and beyond, Amara is driven by the belief that setting kids on the right path from a young age will help them live better, feel better and think better for the rest of their lives. Amara’s revenues have grown by more than 400% since January 2021, and the brand’s success has drawn media coverage from business news outlets including Forbes and TechCrunch.

Market Outlook

According to an August 2021 report from Bloomberg Intelligence, the plant-based foods market is expected to experience explosive growth, comprising up to 7.7% of the global protein market by 2030 at a value of over $162 billion, up from $29.4 billion in 2020. Bloomberg notes that plant-based alternatives are here to stay, and that consumption will grow rapidly. Plant-based food sales in 2020 grew twice as fast as overall food sales, according to Polaris Market Research.

Pulse proteins (fava, yellow pea, etc.) are a foundational ingredient to most plant-based foods due to their high protein content and their readily available, affordable supply.

Many analysts view the food tech market as similar to the early days of the Internet in that plant-based foods represent a worldwide secular trend of steady growth and potential that will revolutionize the way society functions and people experience nutrition.

The sector continues to experience significant M&A transactions. Recently, Sol Cuisine was acquired by PlantPlus Foods LLC, a major South American protein producer, in an all-cash transaction valued at approximately $126 million, or 6x revenue.

Management Team

Marc Aneed is President and Director of Eat Well Group. His 20-year career in CPG started at The Quaker Oats Company/PepsiCo, where he worked on iconic brands like Gatorade. He previously was at Glanbia PLC, a global nutrition company, where he led Amazing Grass, a leading plant nutrition and supplement company with over $100 million in retail sales. He also led Glanbia’s Sports Nutrition brands in North America with over $750 million in retail sales. Mr. Aneed has launched dozens of successful consumer products, driving over $1 billion in collective retail sales.

Mark Coles is the company’s Chief Investment Officer. He is a veteran CPG senior executive specializing in the plant-based foods sector. For the past decade, Mr. Coles has spearheaded global plant-based start-up initiatives, culminating in a 2020 acquisition by an international New York Stock Exchange-listed food ingredient company. He has over 25 years of experience in CPG-focused strategy, mergers and acquisitions and project financing.

Patrick Dunn is Eat Well Group’s Vice President, Finance. He is the founding partner of Dunn, Pariser & Peyrot and has a track record of building highly successful agribusinesses throughout North America and other international markets. As a testimony to his business portfolio work, Mr. Dunn and his firm have won multiple industry awards for accounting, finance and business management.

Barry Didato is the company’s Vice President, Strategy. He is focused on the development of strategic revenue channels, sales partnerships, and international distribution for Eat Well Group. Mr. Didato brings extensive strategic sales capabilities and an extensive network of contacts in the industry to the company. Prior to joining Eat Well Group, he served for over 18 years as a senior advisor for several ultra-high net worth family offices and numerous innovative wellness, nutrition, medical, and food businesses.

Strategic Advisory Board

HRH Prince Khaled bin Alwaleed bin Talal Al Saud, Founder and Chief Executive Officer of KBW Ventures, is a firm supporter of clean energy and the humane treatment of animals. He is also a vocal supporter of the private sector in the Middle East. A member of the Saudi Arabian Royal Family, Prince Khaled was born in Stanford and spent his youth in Riyadh under the mentorship of his father, philanthropist HRH Prince Alwaleed bin Talal Al Saud, Chairman of Kingdom Holding Company. He is also the Founding Chairman of KBW Investments and serves across several boards. He invests in an array of successful but diverse global businesses – from promising technology startups to established companies. Today, with holdings on three continents, Prince Khaled stands at the gateway between the Middle East’s evolving economies and the Western world. Consistently, Prince Khaled’s focus is on ventures and ideas at the intersection of innovation and economic growth.

Jeff Dunn has over 30 years of experience in agriculture and packaged food, including senior leadership positions with Bolthouse Farms, Campbell Soup Company and The Coca Cola Company, among others. He is an Operating Partner at Butterfly and focuses primarily on the agriculture & aquaculture and food & beverage product sectors. Prior to joining Butterfly, Mr. Dunn was the President of the Campbell Fresh division of Campbell Soup Company from 2015 to 2016, where he was in charge of building Campbell’s scale and accelerating its growth in the rapidly expanding packaged fresh segments and categories across the retail perimeter.

Eat Well Investment Group Inc. (OTC: EWGFF), closed Thursday's trading session at $0.173, off by 8.9234%, on 4,237 volume. The average volume for the last 3 months is 4,237 and the stock's 52-week low/high is $0.13158/$1.00.

Recent News


The QualityStocks Daily Newsletter would like to spotlight SRAX Inc. (NASDAQ: SRAX).

SRAX Inc.'s (NASDAQ: SRAX) is a digital marketing and consumer data management technology company. SRAX’s technology unlocks data to reveal brands’ core consumers and their characteristics across marketing channels.

Through its BIGtoken platform, SRAX has developed a consumer-managed data marketplace where people can own and earn from their data, thereby providing everyone in the internet ecosystem choice, transparency and compensation.

SRAX’s tools deliver a digital competitive advantage for brands in the CPG, automotive, investor relations, luxury and lifestyle verticals by integrating all aspects of the advertising experience, including verified consumer participation, into one platform.

SRAX Verticals

  • SRAX Core: SRAX Core is a custom digital media management platform that enables brands and agencies to surpass the challenges of omnichannel marketing campaigns. It offers one comprehensive dashboard to manage digital media campaigns, inventory and reporting.
  • SRAX Social: SRAX Social is a free social media management tool that makes it easy for brands, agencies and individuals to grow their digital presence. It offers free and unlimited users, Facebook auto boosting, and a custom analytics dashboard. Its managed services team can also build and execute marketing plans for your unique specific needs.
  • SRAX IR: SRAX IR unlocks stock buyers’ behaviors and trends for issuers of publicly traded companies. The platform provides insights on shareholders and market makers, investor relations management, shareholder outreach tools and data-driven marketing.
  • SRAX Auto: SRAX Auto unlocks auto intenders’ data to create measurable connected experiences on the road to purchase. It offers proprietary auto intender profiles, multi touchpoint communication and custom location-based ads.
  • SRAX Shopper: SRAX Shopper delivers a cross channel, premium digital experience at scale to high value shopper audiences. It offers proprietary shopper profiles, cost per click pricing, and custom text and add to cart ad units.
  • SRAX Lux: Launched in June 2019, the SRAX Lux platform targets and reaches luxury consumers at luxury retail stores, high-end art, music, film, fashion and sports events, across all consumer devices.


BIGtoken, available for download on the App Store and Google Play, revolutionizes data collection. BIGtoken is a platform that creates a secure and transparent environment for consumers to own and earn from their data. To date, there are 15.9 million BIGtoken registered users worldwide.

The optimization and monetization of data is a multibillion-dollar business. Worldwide spending on big data and business analytics solutions reached $166 billion in 2018 and is projected to surge to $260 billion by 2022. BIGtoken’s consumer vision is committed to delivering choice, transparency and compensation to the individual.

Through BIGtoken, consumers earn rewards when they opt into sharing their data and when that data is purchased. Consumers decide what data is shared, who can buy it and how it’s used, and advertisers reach real, responsive audiences. The benefit of this is two-fold: consumers know how their data is used and advertisers gain verified consumer data for targeting.

Users of the BIGtoken app can officially be paid in cash or gift cards in exchange for giving brands access to their anonymized data, answering questions, checking into locations, recruiting new members, and more. Users can deposit their earnings directly into PayPal accounts or be paid through gift cards from favorite retailers such as Walmart.

SRAX has also partnered with several high-profile, nonprofit associations to provide BIGtoken users the ability to donate their earnings. Partnerships include the American Heart Association, dedicated to fighting heart disease and stroke; HealthCorps, which helps high school students make better choices about health and physical fitness; and the ALS Association, which recently launched its Challenge Me campaign.

International Expansion

BIGtoken is formally launching into several international markets and partnering to foster local support. SRAX recently signed a joint venture with the Yash Birla Group to launch BIGtoken in India. Based in Mumbai, the Yash Birla Group, one of India’s largest conglomerates, has diversified interests in consumer and industrial products.

The partnership will bring BIGtoken’s platform to India, which has a digital population of 627 million. The India digital advertising market is $3.6 billion and is set to grow at a compound annual growth rate of 32%, making it one of the largest growing digital ad markets in the world.

SRAX Mexico is led by Moe Avitia, who has more than 18 years of experience in business development and building high-tech teams. SRAX Mexico includes a team of 90 employees, including 70 engineers.

BIGtoken Europe is currently evaluating data centers in individual countries for privacy laws.


Christopher Miglino is CEO and founder of SRAX. He has spent the past 20 years working in the digital advertising space and has successfully launched and sold two internet companies. Both of these companies were sold to publicly traded companies on the NASDAQ. He has a detailed understanding of how technology interacts with brands.

Kristoffer Nelson is COO of SRAX and a founding member of BIGtoken. With over 15 years of technology and creative business experience, Nelson has been a guest speaker for Loyola Marymount University among other academic institutions, the National Association of Broadcasters, the IAB and numerous other professional and media organizations.

SRAX Inc. (NASDAQ: SRAX), closed Thursday's trading session at $2.5, up 2.8807%, on 43,189 volume. The average volume for the last 3 months is 41,049 and the stock's 52-week low/high is $1.75/$6.50.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.